CONTENTS

01 02 03

Strengthening Foundation Crafting Medicines with Care Cultivating Talent

About This Report 03 Advancing Steadily Safeguarding Health Harnessing Collective Wisdom

Chairman’s Message 04

Enhancing Governance Efficiency 14 Keeping Quality Commitments 21 Implementing Compliant Employment 42

Board of Directors’ ESG Statement 05

Strengthening Risk Management 15 Focusing on Technological Innovation 28 Empowering Employee Growth 45

About Salubris 06

Practicing Business Ethics 17 Putting Patients First 35 Unlocking Employee Potential 48

ESG Governance 09

Information Security and Privacy Protection 19 Industrial Synergy and Common Prosperity 38 Ensuring Health and Safety 50

04 05

Greening the Future Serving Society

Fostering Ecological Harmony Enriching Lives

Appendix 75

Responding to Climate Change 55 Deepening Inclusive Healthcare 70

Strengthening Environmental Management 59 Building a Better Society Together 73

Practicing Resource Conservation 60

Promoting Green Operations 66Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 03

About This Report Chairman’s Message Board of Directors’ ESG Statement About Salubris

A bout This Report

This report is the first Environmental Social and Governance (ESG) Report released by Shenzhen Salubris Pharmaceuticals Co. Ltd. ("Salubris" "the Company" or "We").Adhering to the principles of objectivity standardization transparency and comprehensiveness this report details Salubris' practices and performance in the fields of ESG

and sustainable development.| Reporting Scope Balance: This report objectively discloses positive and negative information

avoiding selections omissions or presentation formats that might inappropriately

Organizational Scope: Unless otherwise specified the organizational scope of affect the decision-making or judgment of readers.disclosure in this report includes Shenzhen Salubris Pharmaceuticals Co. Ltd. and its Consistency: Unless otherwise specified the data disclosed in this report are for

subsidiaries within the scope of financial statement consolidation. 2025. We will adopt consistent statistical methods to compile the report based on

Reporting Period: Unless otherwise specified this report covers the period from actual management conditions. Unless otherwise specified the data disclosed in

January 1 2025 to December 31 2025. this report are statistically compiled according to the unified information collection

process and mechanism established by our company to ensure comparability.| Basis of Preparation | Data Sources

This report is prepared in accordance with Self-Regulatory Guidelines No. 17 for

Companies Listed on Shenzhen Stock Exchange—Sustainability Report (For Trial The information and data cited in this report originates from official company

Implementation) and the Self-Regulatory Guidance No. 3 for Companies Listed documents statistical reports and relevant public sources. Unless otherwise specified the currency unit used in the report is Renminbi Yuan(RMB).on Shenzhen Stock Exchange—Preparation of Sustainability Report (2026 Revised

Version). It is also prepared with reference to the Environmental Social and

Governance Reporting Code ("ESG Code") as set out in Appendix C2 to the Rules | Report Access

Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited

and the Global Reporting Initiative (GRI) Standards to ensure readiness for future This report is compiled in both Chinese and English. If there are discrepancies

compliance with relevant HKEX requirements. between the two versions the Chinese version shall prevail. Readers can browse or

download this report online via the following URLs:

| Reporting Principles Salubris Official Website: https://www.salubris.com/

Shenzhen Stock Exchange Website: https://www.szse.cn

Materiality: We attach great importance to the impact of environmental social

and governance matters on various stakeholders. This year Salubris conducted a If you have any questions or suggestions regarding the content of this report

materiality assessment and responded to and disclosed material ESG issues in this please feel free to contact us by phone or letter.report. Hotline: 0755-83867888 Email: investor@salubris.com

Quantitative: This report discloses quantitative data in environmental social and

governance categories to demonstrate our performance in key ESG indicators.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 04

About This Report Chairman’s Message Board of Directors’ ESG Statement About Salubris

C hairman’s Message

2025 was a pivotal year for Salubris Crafting Medicines with Care to and safety we persist in the goal of Serving Society to Advance Public

as we accelerated our transformation Safeguard Life and Health. "zero casualties zero occupational Well-being.through innovation and embarked on a

new journey. We faced the challenges of We regard quality as fundamental to

diseases." By leveraging digital We are dedicated to improving access

management tools and conducting

global pharmaceutical industry changes business and have established a quality to healthcare expanding access to high-regular emergency drills we continue

and the era's sustainability proposition. management system throughout the quality medicines for more patients through

We consistently adhered to the mission entire lifecycle of drugs. From raw material

to enhance our risk prevention and fair pricing strategies and broader access

of "improving patients' lives through procurement to finished product delivery

control and emergency response to medicines at the grassroots level. In

capabilities. During the reporting

exceptional medicines" integrating ESG every stage is subject to rigorous quality the field of public welfare and charity the

concepts into corporate strategy and controls. In the field of technological

period there were no major casualty total donation amount reached RMB 27.1

incidents and zero work-related

operations. This year with compliance innovation we continued to advance million focusing on medical assistance

as the foundation innovation as the product innovation in 2025. XinChaoTuo

fatalities providing a strong safeguard rural revitalization and education support.engine and responsibility as the bond and FuLiAn were successfully launched

for employee health and safety We provided emergency assistance to

we made solid progress towards building and EnNaLuo received approval for dialysis

building a safe and healthy working communities affected by the earthquake

indications further strengthening the environment for employees.a high-quality sustainable development in Myanmar by donating anti-infective

ecosystem. core product portfolio. We focused on the Greening the Future to Advance medicines. We empower rural youth to

Cardiovascular-Kidney-Metabolic (CKM) Ecological Responsibility. contribute to a more sustainable future.Strengthening Foundation to Enable chronic disease treatment field with Salubris always fulfills social responsibilities

Sustainable Growth. cumulative R&D investment reaching RMB We incorporated responding to with practical actions promoting health and

We strictly followed laws and regulations 4.9 billion during the last five years. In 2025

climate change into our strategy hope.we filed 241 new patent applications. Our setting clear carbon reduction targets continuously optimized our corporate actively responding to the "Dual Looking ahead Salubris will continue to

governance structure and built a diversified AI-enabled R&D systems also began to

demonstrate tangible results. We strictly Carbon" goals and green development

deepen its focus on the CKM chronic

board of directors. We constructed

adhere to research ethics strengthen our concepts. Through energy structure

disease treatment with a particular

a comprehensive risk management emphasis on cardiovascular and

system embedding risk management intellectual property portfolio and promote

optimization water resource recycling

responsible technology transfer enabling and refined waste management

cerebrovascular diseases. We are

at the early stages of business activities we significantly improved resource committed to solidifying our position

to ensure the Company moves forward innovative solutions to reach patients utilization efficiency demonstrating as an industry leader and leveraging

steadily in a complex and changing worldwide more efficiently. the Company’s commitment to ESG as a key driver of high-quality

market environment. At the same time we Cultivating Talent to Inspire Vitality. green and low-carbon development development. With more determined

upheld the bottom line of business ethics strategic discipline more solid

deepened anti-corruption and anti-unfair We are "people-oriented" and build a safe

as a pharmaceutical manufacturer.innovation actions and deeper sense

competition mechanisms achieved zero equal and diverse workplace environment. We actively practice the concept of responsibility we will join hands with

corruption incidents throughout the year We provide clear career development of circular economy promoting

packaging reduction and material all employees partners and society and encouraged supply chain partners to pathways implement a diversified incentive to jointly create a green healthy

sign integrity agreements jointly creating system and closely bind individual innovation committed to building a and beautiful sustainable future

a fair ethical and healthy business performance with the Company's long- beautiful future where humans and contributing Salubris strength to the

environment. term goals. In terms of occupational health nature coexist in harmony. cause of human health.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 05

About This Report Chairman’s Message Board of Directors’ ESG Statement About Salubris

Board of Directors’ ESG Statement

The Board fully recognizes the strategic value of ESG and

fully understands the impact of various ESG issues on the

Company’s sustainable development and long-term value

creation and is committed to fully integrating sustainable

development goals into corporate strategy and daily

operations. The Company is gradually incorporating ESG

concepts and standards into corporate governance and

operational management systems in accordance with

relevant regulatory requirements and ESG guidelines.The Company has gradually established a three-level

ESG governance structure consisting of the Governance

Management and Execution Levels providing a robust

organizational framework for ESG management. The Board

is the highest decision-making body and Governance

Level for ESG matters with key responsibilities including

formulating ESG strategies and goals reviewing and

confirming the assessment results of major risks and

opportunities supervising the management of material

ESG-related risks and opportunities and the progress

toward ESG targets on an annual basis and deliberating

the Company’s ESG policies and ESG reports. Meanwhile

the Board pays close attention to stakeholder expectations

values the scientific rigor and rationality of the materiality

assessment process and optimizes ESG strategic goals

and management measures based on the assessment

results of material issues to effectively address and fulfill

stakeholder expectations.This report was reviewed and approved by the Board

before release detailing our ESG governance materiality

identification processes implementation of management

practices and key performance indicators.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 06

About This Report Chairman’s Message Board of Directors’ ESG Statement About Salubris

About Salubris

Company Overview

Founded in 1998 Salubris listed on the Shenzhen Stock Exchange in 2009 (Stock hypertension; EnNaLuo for renal anemia; and XinLiTing for type 2 diabetes. All

Code: 002294). Rooted in China and serving global markets we are an innovative have been included in China’s National Reimbursement Drug List (NRDL). We have

globally oriented pharmaceutical company integrating research and development successively undertaken or participated in more than 70 2 major national science

(R&D) manufacturing and commercialization. and technology programs as well as major national provincial and municipal

We remain committed to our mission of "Improving patients' lives through science and technology projects and have been awarded the China Patent Gold 3

exceptional medicines." With a focus on CKM chronic diseases particularly Award 3 times .cardiovascular and cerebrovascular conditions we are dedicated to safeguarding

life and health. We have established 5 innovative drug R&D centers and 3 medical

device R&D bases worldwide and built innovation platforms covering small Corporate Philosophy

molecules biologics and antibodies peptides and cyclic peptides siRNA and other

small nucleic acid therapeutics in vivo gene editing AI-driven drug discovery

(AIDD) and medical devices. Through continuous innovation and breakthroughs

we strive to address unmet clinical needs.Putting patients first and taking innovative pharmaceuticals and medical devices

as our strategic focus Salubris has developed a globally competitive R&D pipeline

of more than 100 products in the CKM chronic disease area. 6 innovative drugs

have been launched including XinLiTan XinChaoTuo FuLiTan and FuLiAn for

Mission Vision Values

Improving patients' Becoming China's most Goodness begins with

lives through influential innovative integrity

exceptional medicines pharmaceutical company Putting patients first

1 According to PharmaCube data as of January 2026 Salubris Pharmaceuticals ranks second among domestic Chinese

pharmaceutical companies in terms of the number of marketed products with patents still in force and innovative drug with a global presence Building a culture of striving

candidates in development in the CKM therapeutic area.

2 Data source: Internal statistics of the Company.

3 Award years: 2015 2018 and 2019. Awarding authority: China National Intellectual Property Administration (CNIPA).Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 07

About This Report Chairman’s Message Board of Directors’ ESG Statement About Salubris

M ajor Milestones

■ Salubris was established. ■ TaiJia was launched. ■ Listed on Shenzhen Stock Exchange ■ XinLiTan China’s first Category 1.1

(Stock Code: 002294). innovative antihypertensive drug

was launched.

1998 2000 2009 2013

■ XinFuTai our first ■ XinLiTan's compound patent ■ Accelerated internationalization; Salubris ■ TaiJia's formulation patent was

biologic was approved was awarded a gold medal at Biotherapeutics Inc. was established in awarded a gold medal at the 17th

by the NMPA. the 20th China Patent Awards. Maryland USA. China Patent Awards.

2019 2018 2017 2015

■ FuLiTan China’s first domestically developed ■ XinChaoTuo China’s first domestically

fixed-dose combination of an ARB (angiotensin developed co-crystal drug in the ARNI

II receptor blocker) and a CCB (calcium class was approved.Maurora Rapamycin EnNaLuo was approved channel blocker) was approved for marketing.■ ■ ■ FuLiAn China’s first fixed-dose

Drug-Eluting Vertebral and launched. ■ XinLiTing a domestically developed Category 1 combination antihypertensive drug

Artery Stent System was innovative drug for the treatment of metabolic comprising an ARB and a thiazide-like

approved. diseases was approved and launched. diuretic was approved.

2020 2023 2024 2025Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 08

About This Report Chairman’s Message Board of Directors’ ESG Statement About Salubris

2025 ESG Highlights

Strengthening Foundation Advancing Steadily Cultivating Talent Harnessing Collective Wisdom

■ Held 9 Board meetings with a director attendance rate of 100% ■ Annual training coverage rate reached 100% with average training

hours per employee at 59 hours

■ 0 corruption incidents occurred nor were any financial losses caused

by such violations ■ 0 major incidents of employee and contractor casualties or occupational

diseases occurred

■ Completed 2 information security audits; OA system completed the

registration and evaluation for Level 2 of the Multi-Level Protection Greening the Future Fostering Ecological Harmony

Scheme (MLPS)

■ Passed ISO 14001 Environmental Management System certification

■

Crafting Medicines with Care Safeguarding Health Photovoltaic projects cumulatively generated 3.39 million

kWh of clean electricity reducing carbon dioxide emissions by

approximately 1820 tonnes

■ Commercialized Product Release Pass Rate was 100%

■ 0 major accidents violating environmental laws and regulations and major

Market Sampling Inspection Pass Rate was 100%

environmental pollution accidents

■ Total number of product recalls for quality reasons was 0

Serving Society Enriching Lives

■ In the hypertension field successfully launched 4 new drugs

■ R&D investment amounted to RMB 1.266 billion accounting for ■ A total of 32 marketed drugs were included in the NRDL

29.10% of annual revenue

■ Total charitable donations reached RMB 27.1 million including

■ Filed 241 patent applications obtained 63 patent grants maintained cumulative public welfare drugs valued at approximately RMB 7.18

a cumulative total of 392 valid patent grants million; approximately 200 employees and volunteers participated in

■ Customer complaint processing rate was 100% volunteer services contributing a total of 1965 service hoursOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 09

ESG Governance Structure ESG Strategy and Risk Management Stakeholder Engagement Double Materiality Assessment

ESG Governance

Salubris upholds the concept of sustainable development constructing and

continuously improving an ESG governance system aligned with development

strategy and business operations promoting the comprehensive integration Salubris ESG Three-Level Governance Structure

of ESG management into strategic planning and daily operations. The

Company establishes a diversified stakeholder communication mechanism

fully assesses the financial and impact materiality of sustainable development

issues integrates feedback from stakeholders into business decisions and Board of Directors

continuously optimizes sustainable development management mechanisms.■ Lead and oversee ESG matters focus on stakeholder expectations

■

Governance Deliberate and approve ESG strategies short/medium/long-term goals

Level and core management systems

■ Review and approve annual ESG reports and disclosure content of major

ESG issues

Heads of various business and functional departments

coordinated by the Production Center

■

Management Promote the implementation of ESG plans and coordinate across

Level departments

E SG Governance Structure ■ Formulate ESG strategies short/medium/long-term goals and report to the Board

Salubris designates the Board as the highest decision-making body ■ Coordinate ESG data collection and data management across

for ESG governance and constructs a three-level ESG governance departments

structure consisting of the Governance Level Management Level

and Execution Level. The Company clarifies the composition of each

level and implements ESG responsibilities hierarchically ensuring ESG

management is integrated into the Company's operational system and

long-term development strategy. Additionally the Board establishes an Various business and functional departments

Audit Committee under its oversight granting it independent supervision

functions to ensure sustainable development work proceeds in an orderly Execution ■ Integrate ESG goals into daily work specifically implement sustainable

manner and operations remain compliant. Level development initiatives in their respective fieldsOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 10

ESG Governance Structure ESG Strategy and Risk Management Stakeholder Engagement Double Materiality Assessment

ESG Strategy and Risk

Management

Salubris possesses deep insight into throughout the entire cycle of R&D

industry trends carrying out double and innovation quality management

materiality assessments based on talent development and brand

ESG guidelines industry surveys and building. Stakeholder Engagement

stakeholder feedback to identify

Furthermore we comprehensively The Company attaches great importance to continuous company material issues and

sustainable development directions incorporate the identification of

communication and positive engagement with stakeholders

integrating sustainable development sustainability-related risks and

regarding it as an important foundation for improving corporate

governance and ESG management. Through diverse and regular

concepts into corporate strategic opportunities into the Company's risk

planning. We always practice patient- management workflow continuously

engagement mechanisms we maintain open channels for

monitoring and managing ESG risks stakeholder feedback and actively respond to their concerns. centricity firmly fulfill the sustainable Combining industry and operational realities we identify and

development responsibility of through three lines of defense and

establish a sustainable development maintain a stakeholder list incorporate stakeholder expectations pharmaceutical enterprises delve into ESG decision-making clarify sustainable development

into the CKM chronic disease field goal system to ensure the effective

implementation of ESG strategies in priorities and dynamically optimize management strategies.build a strong product portfolio and

commit to embedding environmental all aspects of company management

social and governance requirements and development.Salubris Stakeholder Communication Mechanism

Stakeholders Key Focus Issues Channels of communication

■ Emissions and waste management ■ Responding to climate ■ Risk management ■ Regular reporting ■ Participation in

■ Environmental management and change ■ Corporate governance ■ Site visits meetings/seminars

Government & ecological protection ■ Business ethics and

Regulators anti-corruption

■ Responding to climate change ■ Business ethics and ■ Corporate governance ■ Shareholders' meeting ■ Reception of visitors

■ Product R&D and innovation anti-corruption ■ Stakeholder engagement ■ Announcements ■ Phone calls

Shareholders & ■ Sustainable supply chain ■ Risk management ■ Performance roadshows

Investors

■ Product R&D and innovation ■ Customer service and ■ Access to healthcare ■ Customer satisfaction ■ Customer feedback

■ Product quality and safety rights ■ Patient health and safety survey

Customers & ■ Information security ■ Responsible marketing ■ Business communication

Consumers and privacy protectionOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 11

ESG Governance Structure ESG Strategy and Risk Management Stakeholder Engagement Double Materiality Assessment

Stakeholders Key Focus Topics Channels of communication

■ Resource management ■ Employee training and ■ Risk management ■ Board meetings ■ Daily operational

■ Responding to climate change development ■ Corporate governance management meetings

■ Product R&D and innovation ■ Business ethics and

Directors & Senior ■ Information security and privacy anti-corruption

Management protection

■ Occupational health and safety ■ Employee rights ■ Information security and ■ Employee representative ■ Suggestion boxes

■ Employee compensation and ■ Employee training and privacy protection congress ■ Roundtable discussions

benefits development ■ Employee satisfaction

Employees surveys

■ Sustainable supply chain ■ Risk management ■ Stakeholder engagement ■ Tendering and ■ Qualification and

■ Business ethics and anti- procurement assessment

corruption ■ Thematic exchange ■ Site visits

Suppliers

■ Product R&D and innovation ■ Business ethics and ■ Stakeholder engagement ■ Regular communication ■ Meetings phone calls

■ Sustainable supply chain anti-corruption and exchange and correspondence

Partners ■ Risk management

■ Resource management ■ Public welfare ■ Patient health and safety ■ Volunteer activities ■ Health education

■ Emissions and waste management ■ Access to healthcare ■ Stakeholder engagement

Community & ■ Environmental management and

the Public ecological protectionOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 12

ESG Governance Structure ESG Strategy and Risk Management Stakeholder Engagement Double Materiality Assessment

Double Materiality Assessment Double Materiality Matrix

Salubris follows exchange guidelines and upholds the principle of double materiality.We conducted a double materiality assessment of ESG issues in accordance with

Product R&D and Innovation*

relevant requirements of the Self-Regulatory Guidelines No. 17 for Companies Listed on Responding to Climate Change

Shenzhen Stock Exchange—Sustainability Report (For Trial Implementation) and the High Occupational Health and Safety Product Quality

Self-Regulatory Guidance No. 3 for Companies Listed on Shenzhen Stock Exchange— and Safety*

Preparation of Sustainability Report (2026 Revised Version) and actively respond to Access to Healthcare Responsible Marketing

stakeholder expectations. Combining industry characteristics and business realities Emissions and Waste Management

we balance external concerns and internal impacts comprehensively assessing the Information Security and Privacy Protection Business Ethics and Anti-Corruption

impact materiality and financial materiality of various issues. We initially identified Corporate Governance

Sustainable Supply Chain

"Product R&D and Innovation" and "Product Quality and Safety" as two key issues. After Risk ManagementMedium Patient Health and Safety

stakeholder surveys and internal cross-departmental discussions we clarified issue Customer Service and Rights Protection

Stakeholder Engagement

priorities and completed financial materiality analysis ultimately establishing the 2025 Employee Compensation and Benefits

Employee Training and Development

Double Materiality Matrix4 5. Employee Rights

Environmental Management

and Ecological Protection Energy Management

Double Materiality Assessment Process

Low Public Welfare Resource Management

Identify environmental social and governance (ESG) issues by considering policy

Issue Environmental

trends industry characteristics corporate strategy and stakeholder concerns. This

Identification Social

initial screening covers 22 issues across environment social and governance (ESG).Governance

Assess the actual or potential impacts generated by each issue. Comprehensively Low Medium High

Impact Materiality

consider feedback from various stakeholders to confirm the scope duration and

Assessment Financial Materiality

likelihood of impacts determining the materiality level.Financial Analyze the potential impact of ESG issues on the Company's financial

Materiality performance operational performance and long-term value creation determining Environmental Social Governance

Assessment the financial materiality level. Issues Issues Issues

Result Synthesize the double materiality assessment results identify priority issues for Resource Management Product R&D and Innovation* Employee Business Ethics and

Analysis and further analysis and application and apply the assessment results to ESG strategy Emissions and Waste Product Quality and Safety* Compensation and Anti-Corruption

Implementation risk management and sustainability management practices. Management BenefitsCustomer Service and Rights Risk Management

Energy Management Protection Employee Rights Stakeholder

Environmental Information Security and Employee Training and Engagement

Management and Privacy Protection Development Corporate

4 During the reporting period the Company did not conduct standalone due diligence specifically addressing sustainability- Ecological Protection Access to Healthcare Sustainable Supply Governance

related negative impacts or risks. Therefore "Due Diligence" was not set as a material issue. Responding to Climate ChainPatient Health and Safety

Change Responsible Marketing

5 The "Resource Management" issue already encompasses content related to "Water Use" and "Circular Economy"; the Occupational Health and

"Environmental Management and Ecological Protection" issue already encompasses content related to "Ecosystem and Safety Public Welfare

Biodiversity Conservation" and "Environmental Compliance Management"; the "Emissions and Waste Management" issue already

encompasses content related to "Pollutant Emissions" and "Waste Management"; the "Public Welfare" issue already encompasses

content related to "Rural Revitalization" and "Social Contribution"; the "Product R&D and Innovation" issue already encompasses

content related to "Innovation-Driven Development" and "Ethics in Science and Technology"; the "Sustainable Supply Chain" issue

already encompasses content related to "Equal Treatment of small and medium-sized enterprises (SMEs)"; the "Business Ethics Note: Items marked with * represent Double Materiality Issues.and Anti-Corruption" issue already encompasses content related to "Anti-Commercial Bribery and Anti-Corruption" and "Anti-

Unfair Competition."

Impact MaterialityOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 13

Enhancing Governance Efficiency Strengthening Risk Management Practicing Business Ethics Information Security and Privacy Protection

01

S trengthening Foundation

Advancing Steadily

The company adheres to a compliant

business philosophy aiming to create an

integrity-focused business environment

and continuously deepening business

ethics supervision mechanisms. By

integrating business ethics and risk

control into strategic planning and daily

operations we establish a comprehensive

system covering anti-corruption fair

competition and risk management. With

high-standard business ethics and robust

operating mechanisms we strive to create

long-term value for stakeholders.

9 ■ No corruption incidents occurred this year nor were any financial losses caused by such

number of board violations.meetings held

times ■ Persisting in compliant operations and zero-

tolerance principle the Company was not

100% involved in any corruption-related lawsuits.

■ Completed 2 information security audits;

director OA system completed the registration and

attendance rate evaluation for Level 2 of the Multi-Level

Protection Scheme (MLPS).Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 14

Enhancing Governance Efficiency Strengthening Risk Management Practicing Business Ethics Information Security and Privacy Protection

E nhancing Governance Efficiency Board Diversity

Salubris upholds the concept of board diversity. In the

Salubris regards governance efficiency as a solid guarantee for high-quality selection nomination and appointment of director

development strictly following laws and regulations and regulatory requirements candidates we comprehensively consider gender age

continuously optimizing governance structure and operating mechanisms and nationality cultural background educational background

is committed to building a diverse and independent board team enhancing professional experience skills race competencies

enterprise value and providing solid guarantees for long-term sustainable independence expertise and service tenure. Meanwhile

development. when selecting suitable candidates we are also

committed to gradually increasing the proportion of

female directors. Director selection decisions are based

Corporate Governance on objective conditions such as their overall contribution

Structure to business development holistic value to the Board alignment with succession plans and development

Salubris strictly follows the Company and perform duties according to law; directions and their contribution to maintaining a diverse

Law of the People's Republic of China meeting convening holding and Board composition thereby continuously enhancing the

the Securities Law of the People's voting procedures comply with legal independence professionalism and decision-making

Republic of China and other relevant requirements. In addition the Board has efficiency of the Board.laws and regulations and regulatory established an Audit Committee and as In terms of director independence management the

requirements continuously improving needed nomination remuneration and Company strictly implements relevant standards clearly

the Articles of Association and robust assessment committees. The Board is requiring that independent non-executive directors must

governance structure clarifying responsible for formulating working rules maintain an independent stance and provide objective

authority boundaries and ensuring for special committees regulating their opinions. During the selection process we focus on

compliant and efficient operations. operations and effectively improving reviewing the independence status and relationships of

The Shareholders' Meeting as the core the professional level and execution candidates to ensure effective performance of duties

decision-making body is responsible for efficiency of Board decisions. thereby effectively improving the oversight effectiveness

clarifying strategic directions business

In 2025 the Group held 9 Board and decision quality of the Board further enhancing the objectives and business plans and fairness and transparency of corporate governance.supervising financial and operational meetings with a director attendance

performance. Directors are elected or rate of 100%. As of the end of the reporting period the Board had

replaced by the Shareholders' Meeting a total of 9 directors of which 3 were independent

non-executive directors (accounting for approximately

33%) and 1 was female director (accounting for

Salubris Corporate Governance Structure approximately 11%). The Board members possess diverse

professional backgrounds and industry experience

Shareholders' Meeting covering corporate governance financial management

human resources management pharmaceutical

Board of Directors industry market development and other fields. During

the reporting period all three directors in the Audit

Audit Committee Nomination Committee

Remuneration and Committee and all three directors in the Nomination

Assessment Committee Committee were independent of management.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 15

Enhancing Governance Efficiency Strengthening Risk Management Practicing Business Ethics Information Security and Privacy Protection

S trengthening Risk Management

Salubris has established a sound risk management system clarified management

processes and accurately identifies risks. By continuously deepening risk assessment

and response mechanisms actively cultivating risk culture and improving employee risk

awareness we provide solid guarantees for the Company's steady operation.Risk Management System

A robust risk management system is the core guarantee of the Company's long-

term stable operation. Based on guaranteeing the stability of the risk management

architecture Salubris continuously optimizes management functions at all levels and

integrates risk management into the whole process of corporate governance and

business management. By clarifying the responsibilities of the Audit Committee risk

management department and front-line business departments we effectively improve

the Company's risk management capability.The Company establishes a risk governance architecture with three lines of defense

as the core: The first line of defense consists of various business departments

responsible for identifying and managing risks in daily operations; The second line of

defense consists of the risk management department (Risk Control Finance Legal HR

departments) responsible for formulating risk frameworks and supervising the overall

risk situation; The third line of defense is the Board Audit Committee responsible for

auditing evaluating and supervising the effectiveness of risk management and internal

controls to ensure risk management capabilities align with business operations.Salubris Three Lines of Defense

Defense Line Organization Function

First Line of Defense Front-line business departments Responsible for implementing risk identification and management in daily business activities

Risk Management Department:

Second Line of Systematically promote the identification collection and assessment of compliance risks timely investigate and

Risk Control Internal Audit

Defense sort out potential risk points and promote the effective operation of risk prevention and mitigation mechanisms.Finance Legal HR

Conduct independent and objective audit supervision on the overall compliance management status regularly in

Third Line of Defense Board Audit Committee

accordance with the compliance system requirementsOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 16

Enhancing Governance Efficiency Strengthening Risk Management Practicing Business Ethics Information Security and Privacy Protection

Risk Management Process Risk Management Culture

Salubris has constructed a standardized risk management process providing clear In terms of awareness cultivation

guidelines for risk identification assessment response and monitoring ensuring the and capability building the

Company always maintains growth resilience and vitality in a dynamic environment. Company has constructed a regular

risk management knowledge

dissemination mechanism integrated

risk management concepts into

Salubris Risk Management Process corporate culture and daily business

processes. The Company focused

on carrying out special training

Conduct comprehensive risk assessments closely combining actual business operations and external environment in key areas such as compliance

Risk dynamics to determine the focus of risk control providing solid support for formulating current and next-year risk management R&D safety and

Identification governance strategies. Compile and submit a comprehensive risk management review to the Company's risk information security integrating risk

management functional department to ensure full coverage and effective management of various potential risks. awareness into the training system

committed to enhancing the risk

sensitivity and identification accuracy

of employees at all levels and

Various business departments rely on standardized risk classification criteria regularly coordinating functional effectively improving the awareness of

departments at the same level to collaboratively promote the collection identification and in-depth analysis of risk all employees to respond to risks.Risk information for the next management cycle. Develop a two-dimensional risk evaluation model based on likelihood and

Assessment potential impact to prioritize identified risks systematically identify significant risks at the operational level and ensure

precise proactive risk oversight.Deploy differentiated risk control measures based on assessment results to ensure effective governance of major risks.Establish a risk register compile an annual risk assessment report and complete corresponding internal compliance

approval procedures. The assessment report needs to be submitted to the risk management functional department.Risk Response The formulated risk management solutions must clearly define specific goals outline relevant management and

operational processes and specify resource allocation requirements. Additionally they must include a full-cycle

response strategy covering pre-event prevention in-process control and post-event remediation for key risk events.To ensure major risk control measures are truly implemented establish a continuous monitoring mechanism generate

Dynamic special monitoring reports and implement dynamic tracking of measure execution. Simultaneously regularly report

Monitoring monitoring progress to the Company's senior management to ensure management remains highly attentive to major

risk prevention and control and possesses agile and efficient response capabilities.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 17

Enhancing Governance Efficiency Strengthening Risk Management Practicing Business Ethics Information Security and Privacy Protection

Practicing Business Ethics

Salubris continues to standardize business operations ensuring operational

compliance. By establishing a comprehensive anti-corruption management

system and clarifying anti-unfair competition norms we are committed to creating

a high-quality business environment integrating compliance integrity and fair

competition.Business Ethics Governance Structure

Salubris strictly follows the Criminal Law of the People's Republic of China

the Anti-Unfair Competition Law of the People's Republic of China and the

Interim Provisions on Banning Commercial Bribery and other national laws and

regulations formulating and implementing the Anti-Fraud Management System

for all employees. The Company continuously optimizes the business ethics

management system clarifies employee integrity practice standards and ensures

that business ethics construction work has solid institutional basis and execution

norms. The Company has established a business ethics governance architecture

led by the Board. Managers at all levels bear corresponding management and

leadership responsibilities according to their managed scope ensuring the

specialization and vertical implementation of supervision duties. In addition the

Audit Committee supervises and reviews business ethics compliance to ensure the

business ethics management system continues to run effectively.Anti-Bribery and Anti-Corruption

To prevent fraud strengthen corporate governance and internal control ensure procurement sales finance and human resources. By establishing clear approval

proper business conduct and maintain the Company’s integrity in commercial mechanisms we ensure anti-corruption measures are fully implemented in all

transactions we comply with national laws and regulations including the Anti- business operations. This year no corruption incidents occurred nor were there any

Unfair Competition Law of the People’s Republic of China and the Anti-Money financial losses incurred due to such violations.Laundering Law of the People’s Republic of China. We also fully implement

regulatory compliance requirements such as the Compliance Guidelines for To standardize supplier cooperation practices and develop a clean and

Pharmaceutical Enterprises on Prevention of Commercial Bribery Risks and have transparent business ecosystem the Company has established a strict entry

accordingly established key policies including the Complaint and Whistleblowing mechanism. We actively require suppliers to sign the Integrity Cooperation

Policy the Employee Handbook and the Rewards and Disciplinary Policy. We are Agreement Commitment Letter prior to onboarding and integrate business ethics

committed to constructing a robust and perfect internal management system guidelines and anti-corruption policy clauses into standard contracts. In the current

continuously deepening integrity governance and business ethics construction year over 95% of our procurement expenditure originated from suppliers whose

integrating compliance standards into key business processes such as contracts include business ethics guidelines and anti-corruption clauses.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 18

Enhancing Governance Efficiency Strengthening Risk Management Practicing Business Ethics Information Security and Privacy Protection

Business Ethics Training Whistleblowing Management

Salubris is committed to enhancing employee integrity awareness systematically Salubris strictly follows national laws and regulations formulates the Complaint

carrying out anti-corruption training and awareness campaigns promoting anti- Reporting System and continuously optimizes the acceptance investigation and

corruption culture and ensuring timely receipt of integrity education. The Company disposal mechanisms for petition reporting and problem clues and is committed

continuously optimizes the business ethics training system conducting anti-fraud to promoting relevant work towards standardization and legalization. To strengthen

training and legal regulatory and integrity moral education for new employees. all-staff integrity awareness the Company carries out mandatory compliance

We carry out business ethics education for all employees annually transforming training for new employees and key post personnel and promotes anti-bribery

regulatory norms into employees' voluntary code of conduct. Through thematic and anti-corruption policies through multiple channels such as email internal

training and promotion we deeply carry out business ethics and compliance networks and meetings. In terms of the reporting mechanism the Company

culture immersion effectively enhancing the compliance awareness and self- establishes dedicated email addresses and internal management platforms

discipline spirit of all employees fostering a clean and upright organizational to open and publicize reporting channels ensuring all reporting cases receive

culture and striving to build a distinctive integrity culture unique to the Group. timely fair investigation and feedback. At the same time the Company strictly

implements confidentiality recusal and accountability mechanisms constructing

Case Business Ethics Training a comprehensive whistleblower protection system opening anonymous reporting

channels strictly prohibiting unauthorized disclosure of reporting information

and strictly prohibiting retaliation. This year the Company was not involved in any

corruption-related lawsuits.This year Salubris focused on R&D and production key posts organizing

special business ethics training themed "Trade Secrets." By analyzing actual

cases from various enterprises the compliance awareness and sense of

responsibility of participants were effectively enhanced.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 19

Enhancing Governance Efficiency Strengthening Risk Management Practicing Business Ethics Information Security and Privacy Protection

I nformation Security and Privacy Protection

Salubris adheres strictly to the information security baseline and firmly protects individual privacy rights. The Company

continuously fortifies institutional defenses enhances technological enablement and cultivates organization-wide awareness

ensuring legal compliance throughout the entire data lifecycle thereby safeguarding business innovation and patient rights

with robust governance capabilities.Information Security Privacy Protection

Salubris complies with laws and regulations such as the Data Security Law of the Salubris strictly complies with applicable laws and regulations in its operating

People's Republic of China and has established internal systems including the locations such as the Personal Information Protection Law of the People's Republic

Data Compliance Management Measures the Network and Information Security of China and has established the Personal Information Protection Management

Management Measures and the Cybersecurity Incident Emergency Response Measures to fully safeguard the personal information of patients and trial

Disposal Measures. The Company clarifies that the Director of the Company's subjects while strictly prohibiting any acts that infringe upon individual privacy.Process and IT Department is responsible for leading the Company's information The Company strictly adheres to the principles of "minimum necessity" and "least

security work comprehensively ensuring the legality and standardization of data privilege" regarding personal information collection ensuring that information

management and continuously improving the effectiveness of information security collection and authorization are confined to the minimum scope required

governance. for business operations including the execution of clinical research projects

The Company continues to strengthen the information security system and verifies collaboration with partner units and research data management. At the same

its robustness through internal controls and external certifications. In 2025 the time the Company fully protects the relevant individuals' rights to be informed

Company completed two information security audits; the OA system successfully deletion and restriction of processing. We have also established and publicly

completed the registration and evaluation for Level 2 of the Multi-Level Protection disclosed complaint and reporting channels concerning personal information

Scheme (MLPS) confirming no major risk hazards. Meanwhile we regularly security committing to respond to complaints within 15 working days. During the

conduct information security awareness promotion and specialized training for reporting period no customer privacy breach incidents occurred.newly hired employees ensuring all regular employees participate in the training

comprehensively enhancing employees' security awareness and risk prevention

skills. During the reporting period no major information security incidents occurred

at the Company.During the Reporting Period

2 0 0

number of information major information customer privacy

security audits security incidents breach incidents

occurred occurredOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 20

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

02

C rafting Medicines with

Care Safeguarding Health

Salubris takes product quality as the

foundation of operations and technological

innovation as the core engine. Upholding

the customer-first concept we establish a

safe efficient and sustainable operational

system through enhanced quality control

accelerating technology transfer deepening

responsible marketing and strengthening

supply chain ESG management providing

solid guarantees for public health and high-

quality development.Ensure every batch of products meets registration

standards and internal quality requirements;

commercialized product release pass rate and

29.10 market supervision sampling inspections pass % rate are both 100%.

R&D investment as a percentage Quality audits encompass manufacturing sites

of annual revenue and their associated quality management

systems across multiple product categories

including non-sterile active pharmaceutical

20.23% ingredients sterile active pharmaceutical ingredients tablets and injectables.

percentage of R&D personnel Established a management process from

complaint registration internal collaborative

investigation to rectification feedback; product

quality complaint processing rate is 100%.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 21

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

Keeping Quality Commitments | Product Quality and Safety Management Governance

Structure

Salubris regards quality as the cornerstone and commitment of development

delving into full-lifecycle quality safeguarding. We adhere to high standards The Company establishes an "unified leadership hierarchical responsibility" product

and strict requirements continuously optimizing quality management systems quality and safety management architecture clarifying that the Product Quality

deepening all-staff quality awareness and agile response mechanisms Safety Committee coordinates the General Manager and the Qualified Person

safeguarding public medication safety ensuring that every product stands as a command management and the Qualified Person drives implementation ensuring

solemn promise to life. rapid response and effective resolution of drug quality safety events.Governance Salubris Product Quality and Safety Management Governance Structure

Salubris strictly complies with local laws and regulations continuously improving Product Quality Safety Committee

the product quality and safety management system centered on the Quality Risk

Management the Deviation Management the Corrective and Preventive Actions Responsible for assessing material risks handling significant or

(CAPA) the Material and Product Release the Complaint Management the emergency drug incidents making risk control decisions and addressing other key matters related to pharmacovigilance; responsible for

Adverse Drug Reaction Monitoring and the Emergency Response for Drug Safety conducting risk assessment of drug safety incidents across the Company

Incidents. These clearly stipulate the processes and requirements for drug recalls Decision- determining the level of emergency response issuing directives to

emergency response to drug safety incidents and production quality accident Making Level activate emergency response plans and fulfilling approval responsibilities

investigations ensuring effective control of product quality throughout its full for critical documents associated with pharmacovigilance activities in

lifecycle. accordance with regulatory requirements.General Manager

Applicable Product Quality Laws and Regulations As enterprise person-in-charge and the first person responsible for

quality serves as commander-in-chief of Level 1 Emergency Command

Headquarters responsible for emergency response of especially major or

China International major drug safety events.Quality Head

■ Drug Administration Law of the People's Republic of China ■ EU GMP Guidelines Management

Level As deputy commander of the Level 1 Emergency Command Center

■ Measures for Supervision and Administration of Drug ■ PIC/S PE-009-18 Guide responsible for assisting the commander in conducting assessment

Production to Good Manufacturing discussion and decision-making on drug safety incidents; and as

commander of the Level 2 Emergency Command Center responsible for

■ Good Manufacturing Practice for Drugs (2010 Revision) Practice for Medicinal approving the resolutions of the Level 2 Emergency Command Center

Products

■ Measures for Drug Recalls and leading and directing emergency response operations for significant

■ ICH Q7 Guide to and general drug safety incidents.■ Measures for Reporting and Monitoring of Adverse Drug

Good Manufacturing

Reactions

Practice for Active Qualified Person

■ Technical Guidance Principles for Safety Risk Pharmaceutical The Qualified Person (QP) independently assumes responsibility for the

Communication of Marketing Authorization Holders Ingredients market release of drugs reviews the compliance of each batch and signs

■ Good Pharmacovigilance Practice (GVP) Execution off its release; participates in the quality system self-inspection validation

Level adverse reaction handling and product recall and bears statutory responsibility for the quality and safety of the released drugs.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 22

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

| Drug Safety Management Strategy

Salubris always integrates quality management into the full lifecycle of drug

Salubris attaches great importance to drug safety and pharmacovigilance R&D production and post-market. The Company establishes a management

work constructing a drug safety management architecture coordinated by system covering material management production process control quality

the Pharmacovigilance Person-in-Charge with the Drug Safety Department testing product release review periodic quality review complaint handling and

as the execution hub and the Group Research Institute and various functional product recalls ensuring the safety and effectiveness of every batch of products

departments providing technical support. through professional equipment and standardized processes. Meanwhile the

Company continuously carries out quality training and emergency drills promoting

Salubris Drug Safety Management Structure quality awareness deep into all staff and actively participates in industry quality

management exchanges; multiple practices have received industry recognition.■ Serves as head of Emergency Command Headquarters Hazard

Pharmacovigilance Control Group coordinating and managing drug risk control | Quality Testing After product approval

Person-in-Charge work receiving major situation reports from the Drug Safety ongoing stability study results

Department. The Company places great importance on serve as a critical mechanism

comprehensive quality control throughout for monitoring quality and

■ Establish and improve risk prevention and control monitoring the entire manufacturing process. It is safety risks. This continuous

reporting and warning systems; equipped with a wide range of precision oversight ensures that every

Drug Safety ■ Investigate clustering of adverse reactions/events and regional analytical instruments covering all batch complies with approved

Department distribution; required testing items for pharmaceutical specifications and internal

Collect safety information carry out signal monitoring and products including high-performance quality standards preventing ■ liquid chromatography (HPLC) gas products with quality defects

benefit-risk assessment. chromatography (GC) dissolution testing or potentially unsafe products

systems stability chambers atomic from reaching the market.■ Participate in drug safety event assessment discussion and absorption spectrophotometers (AAS) During the reporting period

Group Research decision-making; gas chromatography-mass spectrometry commercialized product release

Institute Clinical ■ Evaluate correlation of drug safety event data provided by (GC-MS) and liquid chromatography- pass rate and market supervision

Center various departments judge event development trends and mass spectrometry (LC-MS). These sampling inspections pass rate

impact scope. capabilities support a well-developed are both 100%.testing and inspection platform that enables

■ Provide supportive services such as emergency testing and full quality control from raw materials During the Reporting Period

Various Functional inspection technical identification medical retrieval and and intermediates to finished products

Departments summary analysis. ensuring the safety efficacy and consistent quality of pharmaceuticals. In daily quality

management the Company assigns full 100%

responsibility to the Quality Assurance (QA) commercialized product

department for the integration and analysis release pass rate

of production inspection and stability

data and conducts in-depth investigation

and assessment of deviations Out-of-

Specification (OOS) situations and other 100%

quality factors ensuring timely identification market supervision sampling

and systematic tracing of quality risks. inspections pass rateOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 23

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

| Quality Audits

Salubris establishes an annual quality audit mechanism strictly carrying out audit

work according to the Good Manufacturing Practice for Drugs (2010 Revision) and

its appendices of China the PIC/S GMP Guidelines and the EU EudraLex Volume

4 (Good Manufacturing Practice) standards. We regularly carry out systematic

compliance reviews across the Company's production sites. In 2025 the Company

completed multiple quality audit work with audit scope covering non-sterile active

pharmaceutical ingredients sterile active pharmaceutical ingredients tablets

sterile injectables and other categories of production sites and related quality

management systems. Through a combination of on-site inspections and system

evaluations we comprehensively examine the effectiveness of each factory in

quality control risk management and compliant operations ensuring stable quality

and controlled safety throughout the product lifecycle.| Product Recalls

Salubris has established the Product Recall Management Procedures During the Reporting Period

which provide a classified recall response mechanism and define recall

triggers investigation assessment procedures decision-making processes

and requirements for the handling and disposal of recalled products. Upon

identifying quality defects or potential safety risks in marketed products 0 0

the head of quality organizes a comprehensive investigation and quality

and safety assessment determines the appropriate recall level based on products recalls due to product recall

the severity of the potential harm and initiates and implements the recall health and safety issues incidents

plans. Recalled products are verified registered and quarantined by the

Material Control Department. Following analysis and assessment by the

Quality Head the products are handled through supervised destruction

rework or other compliant methods to eliminate safety hazards.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 24

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

| Quality Culture

Salubris has always treated quality and

safety training as a cornerstone of its

quality culture embedding it throughout

the product life cycle. The Company has

established a multi-level training system

that covers all operational sites and

extends across the full pharmaceutical

value chain—from R&D and manufacturing

to testing and distribution. It has also set

clear annual quality training requirements

for all employees ensuring that everyone

from senior management to frontline

operators has the quality and safety

awareness and professional competence

required for their roles. During the

reporting period participation in product

quality and safety training reached 100%.Salubris Quality Culture Training and Awareness Campaign

Initiatives Actions

During the reporting period ■ Conduct emergency response training at least once annually and emergency drills at least once every three years

Emergency Drills to validate the receipt and handling procedures for adverse events thereby continuously enhancing emergency

response capabilities for quality and safety incidents.The proportion of employees ■ Organize at least 1 mock recall activity every three years; exempt if there is actual recall behavior within three years;

Mock Recalls ■ Fully examine the effectiveness of company and distributor recall systems discuss problems and deficiencies

accepting product quality found formulate improvement measures and form written summaries.training was

■ After each quality safety accident organize cross-factory sharing to promote accident experience transmission

Cross-Organization

100% among operating locations; Accident ■ Include management loopholes in annual quality system audit plans promote system optimization through

Experience Sharing

internal audits or management reviews."Xin Xue Tang" ■ Carry out "Product Knowledge Learning Month" activities focusing on core product lines in hypertension treatment

Online Learning metabolic disorders orthopedics and nephrology and systematically delivered specialized training sessions. In

Platform 2025 the activity launched over ten high-quality courses each attracting 900+ to 2000 employees to participate.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 25

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

| Industry Quality Awards

Salubris regularly carries out quality management group activities quality breakthroughs and process optimization

continuously participating in industry quality management result exchanges. Multiple case studies have received

industry recognition and honors providing reference examples for high-quality development of the pharmaceutical

industry.Case Salubris Won Multiple Honors at the National Pharmaceutical Industry Quality Management (QC) Group Achievement Presentation Exchange Meeting

In October 2025 Salubris participated in the 46th National Pharmaceutical Industry Quality Management

(QC) Group Achievement Presentation Exchange Meeting. Selected QC topics covered production

optimization quality control and other fields. Topics around intelligent management of reagents and

standard substances product particle size control and capacity improvement won First Prizes; topics

focusing on improving Chemical Oxygen Demand (COD) and Total Nitrogen treatment efficiency in

environmental station wastewater won Second Prizes; several topics secured the "Best Presentation

Awards."

Salubris Won Multiple Honors at the National Pharmaceutical Industry Quality

Management (QC) Group Achievement Presentation Exchange MeetingOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 26

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

Impacts Risks and Opportunities Management

The Company continuously improves drug risk monitoring and early warning mechanisms. According to national drug

sampling adverse reaction monitoring medical institution and patient feedback etc. we formulate and dynamically

adjust the Company's drug safety risk monitoring scheme proposing analysis and assessment opinions on risk factors

risk levels impact scope urgency and possible harms.Salubris Drug Safety Risk Event Control Measures

Potential Risk Factors Risk Control Measures

■ Revise drug instructions;

Risks Caused by Irrational or

■ Issue Letters to Medical Personnel and Patient Medication Safety Tips;

Erroneous Clinical Drug Use

■ Assign experts for on-site guidance on clinical medication.■ Timely initiate risk assessment work write assessment reports and analyze risk influencing

factors;

Determined as New Adverse

■ If risk may seriously endanger patient life safety or public health immediately take risk

Reactions

control measures such as suspending production sales and recalling products and

report to provincial drug supervision departments.■ Under government guidance carry out proper disposal consolation medical treatment

Post-Event Recovery

compensation insurance claims etc. for affected personnel.The Company implements four-level grading management for drug safety events dividing based on dimensions such

as number of adverse events number of serious adverse events and number of deaths corresponding to different

levels of emergency command systems and reporting time limits. For Level I (Especially Major) and Level II (Major)

events we ensure telephone reporting is completed within 30 minutes and written reports are formed within 1 hour to

properly and timely resolve drug safety events.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 27

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

Metrics and Targets

The Company is committed to

safeguarding public health and life

safety constructing a quality target

system around dimensions such as

product safety and effectiveness recall

notification timeliness emergency

graded response timeliness and the

"Three No-Tolerance" principle for

accident investigations management.We have established a comprehensive

accountability and incentive framework

that recognizes outstanding teams

and individuals for their exceptional

contributions to drug safety incident

response while holding accountable

those responsible for delayed reporting

concealment or negligence or

dereliction of duty in incident handling

thereby ensuring quality objectives are

consistently achieved.Salubris Quality Target System

■ Set commercial product perfect batch rate targets each factory must reach 90% to ensure product safety and effectiveness effectively

Product Safety and Effectiveness reducing product safety hazards.■ With the target of achieving 100% market supervision sampling inspection pass rate we ensure the health and safety of end-consumers.Recall Notification Timeliness ■ Ensure Level 16 recalls notify distributors and medical institutions within 1 day Level 27 within 3 days Level 38 within 7 days.Accident Reduction ■ Reduce repeated occurrences of production quality accidents avoid development and spread of production quality accidents."Three No-Tolerance" principle for ■ The principle requires that the root cause be identified relevant personnel be properly trained and corrective and preventive actions

accident investigations (CAPA) be implemented before an investigation is considered closed.

6 Recalls triggered where use of the drug may or has already caused serious health hazards such as wrong product wrong specification wrong active ingredient chemical contamination leading to serious medical incidents etc.

7 Recalls triggered where use of the drug may or has already caused temporary or reversible health hazards such as labeling errors chemical/physical contamination unsafe packaging containers etc.

8 Recalls triggered where use of the drug generally does not cause health hazards but retrieval is needed for other reasons such as expiry date errors container specification errors etc.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 28

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

F ocusing on Technological Salubris R&D and Innovation Governance Structure

Innovation Level Main Functions

Salubris pursues an innovation-driven development The Company establishes three governance roles: Chief Scientist Project

strategy and has established an integrated framework Management Office (PMO) and Review Meeting Participants.covering R&D governance intellectual property and

■

research ethics. The Company maintains a strong As the academic lead for the project the Chief Scientist has ultimate decision-

commitment to compliance optimizes resource allocation making authority and provides technical guidance ensuring that R&D priorities remain

accelerates translation of research into applications and scientifically rigorous and forward-looking.■

is committed to serving patient health with high-quality PMO is responsible for organizing and coordinating review meetings tracking review Decision-making Level

innovation results. progress records and compiling review reports ensuring process standardization and

transparency.■ Review Meeting Participants are divided into Research Center Level and Group Level

reviewers based on the significance of each review stage; Group Level review scope

Governance covers Director of the Research Institute Vice Director Chief Medical Officer and heads

of Market Finance Production and Quality Centers who make cross-departmental

Salubris takes innovation as the engine and deepens its comprehensive decisions on major projects.focus on the CKM chronic disease treatment area. We

are committed to accelerating translation of frontier

research into applications through system optimization

and mechanism-driven innovation. By delivering more ■ Optimize R&D system organizational structure independently establish Biological Drug

high-quality research outcomes to global patients we aim Innovation Discovery Center and Chemical Drug Innovation Discovery Center reporting

to create shared value that aligns corporate growth with directly to the General Manager to improve response speed;

social impact. ■ Simultaneously establish Small Nucleic Acid R&D Department Biology Department Execution Level

Computer-Aided Drug Design (CADD) Department and Pipeline Strategic Planning

Department forming an R&D matrix covering chemical drugs biological drugs small

| R&D and Innovation Governance nucleic acids peptides and cyclic peptides strengthening synergy efficiency of source

Architecture innovation and strategic management.Salubris strictly follows internal systems such as the R&D

Project Review Management Measures and the R&D

Project Incentive Management Measures formulating the ■ Implement large project system management; Each project sets a Project Leader

R&D System Five-Year (2026-2030) Development Plan to responsible for overall promotion strengthening process control and cross-

provide programmatic guidance for company R&D work. departmental collaboration; Project Operation Level

The Company establishes a layered R&D and innovation ■ Simultaneously enhance management execution and frontline engagement requiring

governance architecture clarifying functions at all levels managers to go deep into frontlines to solve technical process and management

to ensure the R&D system operates in a standardized and problems ensuring effective transmission of governance system at the execution end.efficient manner.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 29

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

Strategy | Leading Industry Development

Salubris has established a multi-dimensional R&D incentive mechanism actively

laid out cutting-edge technologies and continuously enhanced its independent Capitalizing on the strategic opportunity for China's pharmaceutical industry toinnovation capabilities contributing positively to the high-quality development of transition from "Me-too" to "Best-in-Class" and "First-in-Class” Salubris continues

the industry. to increase innovation investment. From 2021 to 2025 cumulative R&D investment

reached RMB 4.9 billion injecting strong momentum into the rapid expansion of the

product pipeline.| R&D Incentive Mechanism The Company has cultivated a significant first-mover advantage in the CKM

chronic disease treatment field centered on cardiovascular and cerebrovascular

Salubris has established the R&D Project Incentive Management Measures diseases. Specifically in the hypertension sector the Company has successfully

adhering to the core principles of "taking strivers as the foundation centering on launched four new drugs. We persist in technology leadership proactively

patient needs and orienting towards project outcomes." This framework builds an deploying an AI-enabled innovative drug development system. By continuously

R&D ecosystem in which employees and the company achieve win-win value. We optimizing CADD (Computer-Aided Drug Design) and AIDD (AI-Driven Drug

have developed five categories of R&D project rewards forming an incentive matrix Discovery) platforms we are dedicated to creating proprietary AI chemical

that covers the entire lifecycle from project initiation and development to technical innovative drug design algorithms to drive a leap in R&D efficiency through

breakthroughs and special contributions. Reward standards comprehensively technological empowerment.consider multiple dimensions such as expected returns development models

registration classifications difficulty coefficients and project progress. Additionally

we have established a key milestone review mechanism spanning the entire

product lifecycle from lead molecule discovery to obtaining production approval.This includes pharmaceutical research preclinical pharmacology and toxicology

trials clinical bioequivalence (BE) trials and Phase I to III clinical studies. Upon

successful review at each milestone teams become eligible to apply for

corresponding bonuses ensuring incentives precisely target the R&D frontline.| R&D Innovation Projects

Salubris is deeply engaged in R&D and innovation focusing on the cardiovascular- From 2021 to 2025

kidney-metabolic (CKM) field while addressing domestic market demands

and clinical pain points with forward-looking deployment for potential external

licensing. Regarding its self-developed innovative drug pipeline the Company

has constructed a complete product pipeline ranging from early discovery to

market registration. Between 2021 and 2025 we cumulatively obtained multiple RMB billion

novel lead compounds and identified several Preclinical Candidate Compounds 4.9

(PCCs) through screening completed numerous Investigational New Drug (IND) cumulative R&D

applications and advanced several varieties to Phase III clinical trials New Drug investment reached

Application (NDA) stages or market approval. We are actively building small

nucleic acid and peptide/cyclic peptide innovation platforms which are now

entering a concentrated period of early discovery transformation and have

successively obtained multiple new PCCs.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 30

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

Impact Risks and

Opportunities Management

Salubris strictly adheres to relevant

laws and regulations on experimental

ethics as well as the requirements

of the World Medical Association's

Declaration of Helsinki (Revised

October 2024). We have formulated

and implemented the Charter for

the Work of the Experimental Animal

Management Committee and Ethics

Committee and the Ethics Submission

Management Procedure covering

animal experiments and human

clinical trial ethics in their entirety to

ensure full compliance throughout the

R&D process.| Animal Experiment Ethics

The Company has established two independently We implement a pre-approval mechanism endpoints; experiments are terminated

operating specialized institutions: the Experimental where projects cannot proceed without immediately upon triggering these

Animal Management Committee and the approval ("review first then conduct; no standards to prevent unnecessary

Experimental Animal Ethics Committee responsible review no implementation") upholding suffering. During the reporting period

for management supervision and ethical review the 3R principles (Replacement Reduction no violations of animal experiment

respectively. The Management Committee Refinement) for animal use. Standardized ethics occurred.oversees facility operations daily supervision forms ensure all review processes are

and penalties for violations; the Ethics Committee documented and archived. We provide

focuses on project review ongoing supervision and training on animal experiment operations During the reporting period

animal welfare assurance. Committee members including acclimatization feeding

include veterinarians researchers and quality administration and blood sampling

management personnel serving three-year terms to minimize harm to animals. In pain

with regular rotations. The committees convene at management we monitor anesthetic No violations of animal

least once annually to evaluate its operations. responses in animals and set clear humane experiment ethics occurred.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 31

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

| Human Clinical Trial Ethics

To ensure the standardized conduct of drug clinical trials and the scientific validity accuracy and reliability of data and

results while safeguarding the rights and safety of trial participants we will strictly adhere to the approved protocol and

applicable Chinese laws and regulations. All trial activities will be conducted in compliance with the World Medical Association's

Declaration of Helsinki (Revised October 2024) ICH E6 (R3) GCP and the Good Clinical Practice for Drug Trials (2020 Edition) During the reporting period

with all relevant responsibilities duly fulfilled.The rights safety and well-being of trial participants are the paramount considerations and shall take precedence over

scientific and societal benefits. Ethical review and informed consent serve as fundamental safeguards for protecting

participants' rights and safety. We strictly uphold core ethical principles—including informed consent privacy protection and

risk control—to ensure full compliance with national regulations and internationally accepted standards throughout the trial. No violations of human

No clinical trial shall commence without prior approval from the Ethics Committee (EC). Throughout the study the trial will clinical trial ethics occurred.be conducted in strict accordance with the approved protocol. Any amendment to the protocol must be implemented only

after it has been communicated to and agreed upon by the sponsor and subsequently re-approved or filed with the Ethics

Committee unless such measures are necessary to protect the safety rights and welfare of trial participants.Salubris Human Clinical Trial Ethics Management System

■ The Clinical Research Project Manager (CPM) coordinates document preparation and review to ensure consistency of submission versions

Initiation Phase across centers.■ Clinical Research Associates (CRAs) precisely align with center review requirements tracking progress until written approval is obtained.■ Strictly fulfill dynamic supervision duties timely update documents involving trial participants safety report safety information such as

Execution Phase serious adverse events (SAEs) protocol deviations and pregnancy data within prescribed timeframes and regularly submit the Clinical

Research Periodic Progress Reports.Conclusion Phase ■ Properly archive ethics close-out documentation ensuring all documents are completely saved for full-process traceability.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 32

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

| Intellectual Property Management

Salubris complies with laws such as the Patent Law of the People's Republic of China and strictly follows

internal systems including the Patent Management System the Trademark Management System the

Confidentiality System and the R&D Project Review Management Measures to ensure effective protection

and application of intellectual property rights. The person primarily responsible for intellectual property

is included in the list of participants in research center-level review meetings ensuring an independent

voice for IP perspectives in project initiation and key decisions at critical project stages thereby avoiding

infringement risks at the source and expanding technical value.In terms of protection strategy the Company systematically advances efforts across three dimensions:

Salubris Intellectual Property Protection Measures

Strategic Dimension Core Measures

■ For listed innovative drugs collaborate with business departments to deeply explore

IP Protection for

technical details continuously extend peripheral patent layouts and strengthen the

Innovative Drug Products

patent defense system for innovative products.■ Plan overseas application paths for core patents in advance based on external

licensing needs.Overseas Rights Layout ■ Collaborate with overseas patent attorney teams that bring a global perspective to

provide customized IP support for outbound products safeguarding legal rights in

global markets.■ Closely track changes in industry policies and regulations and adjustments in patent

Dynamic Maintenance examination standards across countries establishing a flexible patent portfolio

and Optimization management mechanism to timely optimize patent layout and maintenance

strategies.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 33

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

Salubris Participated in the "Law Interpretation Through Ten Cases" – Interpretation of Typical

Case Patent Reexamination and Invalidity Cases in 2025

Salubris organized employees related to intellectual property management to participate in the "Law Interpretation

Through Ten Cases" event hosted by the Patent Reexamination and Invalidation Department of the China National

Intellectual Property Administration. The event selected ten high-profile influential and guiding typical cases

from 2025 to deeply interpret patent examination standards and clarify patent protection rules. Through this

learning activity Salubris continuously strengthened the professional capabilities of its IP management team

improved compliance levels in patent portfolio risk prevention and rights maintenance and provided more solid

IP protection support for innovative drug R&D achievements.During the reporting period

241

patent applications filed

Participate in the working Exchange for the Demonstration Internal Study on Patent Invalidation Cases

and Creation of Intellectual Property Powerhouse

Construction

63

In 2025 Salubris achieved significant results in intellectual property work. The Company filed 241 patent applications including

226 invention patent applications and obtained 63 new patent grants including 56 invention patent grants. As of the end of new patent grants obtained

the reporting period we had cumulatively obtained 392 valid patent grants providing a solid legal and technical barrier for

continuous innovation.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 34

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

Metrics and Targets

Salubris maintains high-intensity The Company has constructed a technological innovation target system covering

technological investment allocating four dimensions breaking down strategic goals into annual execution plans for

resources in both funding and 2026–2030 to form a trackable and assessable target management mechanism.manpower.Salubris Technological Innovation

Salubris Technological Innovation Targets

Investment Indicators

During the reporting period Obtain approval of multiple new products or

Growth Goals

new indications;

RMB 1.266 billion

R&D investment amount

29.10 Internationalization Promote multiple products for overseas % Goals licensing or overseas sales;

R&D investment as a percentage

of annual revenue

827 Competitiveness Maintain CKM chronic disease clinical R&D

Goals pipeline among the top tier domestically;

number of R&D personnel

20.23%

percentage of R&D personnel Organizational Strengthen organizational mechanisms and talent

Development Goals teams aligned with innovative R&DOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 35

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

Putting Patients First Salubris Customer Service Governance System

Salubris has consistently upheld its business philosophy Company’s ■ Exercises ultimate authority regarding significant product quality complaints and the handling

of "Goodness begins with integrity" and adhered to the Head of Quality or recall of marketed products.core value of "putting patients first." We regard customer

trust as the cornerstone of the Company’s long-term and ■ Serves as the unified external contact window responsible for full-chain management from

sustainable development. Grounded in the characteristics receipt transfer process communication to result feedback and negotiation ensuring timely

of the pharmaceutical industry we serve five key groups: and transparent complaint handling;

healthcare institutions and medical professionals ■ Establishes and maintains complaint ledgers regularly analyzes complaint trends for each

commercial and channel partners retail outlets patients Quality Center variety and feeds back prominent quality issues to the production side to drive rectification

and their families and overseas customers and partners. measures;

We are committed to building a service ecosystem that ■ Responsible for standardized organization archiving and maintenance of all complaint

covers the entire product lifecycle. handling records and related document files ensuring compliance and traceability of the

quality management process.■ Sales Department: Acts as the front-end information hub responsible for collecting and initially

Optimize Service verifying customer complaint details assisting in communicating handling solutions with

customers when necessary and cooperating with investigations;

■ Production Department: Responsible for investigating root causes of complaints drafting

| Customer Service Governance System Business investigation reports formulating and implementing corrective and preventive measures and

Departments

Salubris has built a customer service governance providing technical support on product usage;and Functional

system led by the Company's Head of quality centered ■ Quality Control Department: Responsible for conducting retention sample or sample testing Departments

on the Quality Center's customer service department issuing analysis reports to assist in investigating causes of out-of-specification or abnormal

and coordinated by multiple departments forming situations using scientific data;

an organizational guarantee mechanism with clear ■ Other Functional Departments: Provide professional support in medical and technical fields for

responsibilities and rapid response. complaint handling to ensure accurate and reliable technical judgment for complex problems.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 36

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

| Customer Service clock on working days and immediate safety information is reported within

Guarantee Mechanism archiving of voice messages during

24 hours effectively resolving potential | Customer Satisfaction

non-working hours with dedicated risks. After receiving complaint

follow-up. Meanwhile we continuously information customer service

The Company continues to improve The Company conducts satisfaction enhance the professional capabilities specialists complete initial registration

its customer communication surveys with consulting customers of the customer service team and validity judgment based on the

management system formulating and every half year transforming requiring staff to strictly follow "Complaint Handling Coordination

strictly implementing internal systems customer feedback into motivation internal regulations such as the Drug Table" and convey valid complaints to

such as the Product Complaint for improving product quality and Adverse Reaction Reporting and the factory's Quality Assurance (QA)

Handling Management Procedures driving simultaneous upgrades Monitoring Management System and department within 48 hours to initiate

and the Incoming Call Answering in service quality and customer master product knowledge ensuring investigation. During the investigation

and Message Management. We experience.professionalism and reliability in every phase progress is synchronized

integrate diverse channels set up interaction. periodically; if necessary on-site visits

dedicated customer service hotlines are arranged. Investigation results During the reporting period

comprehensively covering quality are reviewed by the QA manager and

complaints medication consultations | Customer Complaint the person responsible for quality at

and adverse reaction reports the plant before being uniformly fed

extending feedback to terminal Handling back to the customer by the customer

networks including distributors service specialist. During the reporting 0

hospitals and pharmacies ensuring The Company has established a period the Company accepted a complaint events occurring

all complaints are included in a management process from complaint total of 67 customer complaints with

unified tracking and handling process. registration internal collaborative no major complaint events occurring.We strictly enforce standardized investigation to rectification feedback. All complaints achieved a 100%

answering norms and message For quality-related complaints processing rate. 100%

management processes ensuring cross-departmental root cause

professional response around the investigations are initiated to ensure complaint processing rateOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 37

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

Responsible Marketing

Salubris integrates the concept of responsible marketing into every link of commercial activities. By creating a fair competition

market environment standardizing academic promotion behaviors and strictly observing professional ethics the Company is

committed to building a transparent healthy and sustainable pharmaceutical marketing ecosystem guarding public health.| Responsible Marketing monopoly agreements and abusing non-compliance incidents involving eliminating any improper behavior. For

market dominance. For high-risk product information labeling or discovered problems we adhere to a

Management scenarios involving communication marketing communications related to "zero-tolerance" principle immediately

of competitively sensitive information false marketing. initiating rectification procedures

Salubris always abides by the joint sales and procurement industry and implementing accountability

principles of fair competition and standard setting and bidding strict mechanisms continuously promoting

honest operation ensuring all pre-approval mechanisms must be | Responsible Marketing the standardization and transparency

marketing means comply with local followed requiring approval from Audit construction of the marketing system.laws and regulations such as the Anti- legal and risk control departments. It

Monopoly Law of the People's Republic is strictly prohibited to use algorithms

of China. The concept of responsible The Company has established a data advantages or platform rules

marketing is clearly defined in systematic responsible marketing to exclude or restrict competition.the Anti-Monopoly Management audit mechanism conducting

| Responsible Marketing

Compliance responsibilities are

System and integrated into the internal audits and special audits Trainingincorporated into the performance

entire process of drug information annually to comprehensively review assessment of marketing post The Company continues to optimize

dissemination and professional the compliance authenticity employees urging them to and transparency of marketing the compliance and responsible academic exchanges conveying consciously regulate professional

product information in a scientific activities. Audit scope covers key

marketing training system adopting

behavior and observe the bottom diverse modes such as offline lectures

accurate and transparent manner links such as promotional materials line of professional ethics jointly expense reimbursement meeting online studies mentorship guidance to safeguard medical decision- creating a clean healthy and orderly

making and patient life safety. The management and interactions with

and thematic seminars to enhance

marketing ecosystem. In 2025 the stakeholders ensuring all marketing the depth of interaction and practical Company prohibits implementing Company did not experience any activities focus on patient interests and effectiveness of training.During the reporting period

0 non-compliance incidents involving product information labeling

or marketing communications related to false marketing.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 38

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

Industrial Synergy Salubris Supplier Management Process

and Common

The Company strictly complies with internal documents such as the Raw Material and Packaging Supplier Entry

Prosperity Standards setting differentiated "mandatory" and "reference" items for manufacturers and traders for entry evaluation Entry

verified through Tianyancha checks on-site inspections third-party surveys etc. Evaluation items include quality

Salubris deepens full-lifecycle supplier standards price scale of personnel Health Safety and Environment (HSE) management risks and credit status.management committed to building

a robust and efficient supply chain

system. The Company strengthens

ESG risk identification and control The Company builds a regular quantifiable supplier performance evaluation system achieving full-cycle performance

capabilities achieving common control through a combination of annual comprehensive assessments and quarterly special dynamic evaluations. Evaluation

prosperity and shared responsibility Evaluation results are linked to cooperation opportunity allocation share adjustment deepened collaboration and exit

through synergy joining hands elimination.with supplier partners to create a

sustainable ecosystem of shared

value.At the beginning of each year the Company formulates a supplier grading plan for the year according to the

Annual Procurement Plan & Strategy dividing suppliers into core suppliers key suppliers general suppliers and low-

Supplier Management performance suppliers taking differentiated management measures.Salubris strictly complies with the laws ■ Core Suppliers: Deeply synergistic in technology capital or strategy and crucial to business; deep cooperation is

and regulations in the jurisdictions Tiered ensured through high-level mutual visits and early project intervention.where it operates. The Company Management ■ Key Suppliers: Preferred suppliers with large procurement amounts high dependency or excellent performance;

has established internal policies and close interaction is maintained through long-term agreements and technical cooperation.procedures including the Procurement ■ General Suppliers: Qualified or not subject to performance assessment; divided into A B and C categories based on

Management Policy and the Supplier performance. Resources are appropriately tilted towards Class A suppliers on the basis of fair competition.Management Measures to develop a ■ Low-Performance Suppliers: Those with safety/quality accidents or substandard performance; business restrictions

comprehensive supplier management backup finding and gradual elimination measures are taken.process that covers onboarding

evaluation tiered management

and exit thereby directing resources

toward high-performing compliant

and quality suppliers.The Company resolutely implements a supplier rectification and exit mechanism. For suppliers with minor compliance

flaws or management irregularities time-limited rectification is required; for those with delayed rectification weak

Exit willingness or recurring problems introduction or cooperation is suspended; for those with major safety hazards

environmental violations serious quality issues commercial fraud illegal operations refusal to rectify or failed

rectification they are blacklisted and existing cooperation is terminated.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 39

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

The Company treats small and medium-sized enterprises equally adhering to Supply Chain ESG Management

principles of fairness transparency and good faith performance of obligations

establishing standardized unified and strict supplier payment and payment terms Salubris has integrated ESG concepts and compliance requirements into the

management systems. All payments are strictly executed according to formal entire supply chain lifecycle. We implement end-to-end oversight from supplier

contracts with account periods preset in the system. Regardless of supplier size qualification and contracting to exit. This process covers all new suppliers requiring

cooperation cycle or regional differences we treat everyone equally avoiding them to fulfill their committed responsibilities in accordance with the suppliers'

unjustified delays or malicious withholding of accounts effectively protecting the social responsibility and code of conduct. Meanwhile we carry out online and

legitimate rights and interests of small and medium-sized suppliers and various offline ESG exchange activities achieving full coverage of key suppliers actively

cooperative parties. In 2025 the Company had no overdue payments to small and promoting sustainable development concepts urging partners to integrate

medium-sized enterprises. excellent ESG practices throughout production and operation processes jointly

pushing the overall supply chain towards green and sustainable upgrades.As of the end of the reporting period the Company had a total of 2594 suppliers.Supplier management data is as follows:

Salubris Supplier Management Data Salubris Supplier ESG Management Mechanism

Indicator Unit 2025

■ Require suppliers to strictly comply with national and local

Environmental environmental laws and regulations take effective measures to

Mainland China / 2584

Number of Dimension reduce environmental impact and promote green production and

Suppliers by sustainable development.Region Hong Kong Macao Taiwan and / 10

Overseas

■ Prohibit suppliers from employing child labor and using forced

Number of Key Suppliers / 308 labor requiring them to guarantee wages and benefits for all

employee groups;

■ Require suppliers to provide safe and hygienic working

Suppliers Certified by ISO 14001 System / 186 Social environments strengthen employee health and safety training and

Dimension

prevent occupational diseases and work injuries;

■ Require suppliers to respect employees' rights to freedom of

Suppliers Certified by ISO 45001 System / 169 association and collective bargaining eliminating any form of

Supplier discrimination.Certification

Suppliers Certified by ISO 9001 System / 293

■ Prohibit any form of corruption and bribery;

Suppliers Certified by Other

/ 130 ■ Conduct business in a commercially ethical manner ensuring fair

Certifications Governance competition;

Dimension

■ Protect all confidential information or materials provided by the

Suppliers Using Eco-friendly Materials and Circular

/ 21 Company and its business partners.PackagingOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 40

Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity

The Company has built a regular risk management system covering compliance quality delivery environmental safety supply disruption and ESG dimensions. A

procurement risk management group is established defining "zero supply disruption zero violation" management goals implementing full-cycle control of pre-event

prevention mid-event control and post-event review. In terms of evaluation mechanisms we adopt a mode combining daily-triggered periodic and special assessments

where production materials execute quarterly routine evaluations to ensure timeliness and comprehensiveness of risk identification. During the reporting period after

rigorous assessment no suppliers with negative factors related to labor environment etc. were found effectively safeguarding supply chain safety and stable operation.Salubris Supply Chain Risk Management Process

Risk Identification Risk Analysis Risk Grading Risk Disposal Risk Review

The procurement risk The procurement risk Risks are classified into three ■ High Risk: Real-time tracking and Review the situation of risk

management group sorts management group analyzes levels dynamically adjusted reporting to senior management. occurrence effectiveness

out potential risks in each link the causes probability scope of according to conditions and Special disposal plans are of disposal measures and

and category of procurement impact and losses of risks. state changes: formulated submitted for approval existing problems providing

submitting a risk identification list. according to amount and nature dynamic control measures

■ High Risk: High probability of

levels and key difficult matters are and optimization suggestions

occurrence severe impact;

recorded throughout the process. compiling annual risk event

■ Medium Risk: Relatively high

■ Medium Risk: Monthly or weekly reports.probability significant impact;

reporting to responsible

■ Low Risk: Low probability

departments; relevant departments

limited impact.jointly dispose and track progress

and results throughout.■ Low Risk: Quarterly communication

within business departments

included in daily management.The Company is committed to comprehensively enhancing supply chain resilience establishing a full-process quality traceability system. By implementing routine sampling

inspections conducting regular on-site audits and ensuring timely corrective actions the Company effectively mitigates quality risks and maintains consistent quality of

supplied products. Meanwhile we implement diversified procurement resource backup domestic substitution and safety inventory strategies to resolve single-dependency

and capacity bottlenecks at the source building multi-level buffering mechanisms to ensure safe and sustainable supply chain operation.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 41

Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety

03

Cultivating Talent Harnessing

Collective Wisdom

Salubris adheres to a people-oriented

development philosophy regarding

employees as the core driving force

of sustainable development. Through

continuously improving the employee

management system the Company has

built a safe equal diverse and inclusive

work environment. Focusing on employee

protection occupational health and

safety and talent development systems

the Company constantly strengthens

its institutional foundation optimizes

management practices promotes

shared growth between employees and

the enterprise and provides solid talent

support for high-quality development.No 100% 59

violations training coverage average training Welfare support is provided including paid

such as forced rate hours per annual leave health checkups and nursing

labor or child labor employee rooms. Online and offline communication

occurred during channels are kept open and annual

the year satisfaction surveys for all employees are

conducted.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 42

Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety

Compliant and Equal fairness impartiality and transparency. Promoting Equality and Diversity

Employment This ensures that the entire employee Salubris embeds respect for human

Implementing hiring process strictly meets legal and To maintain an equal employment regulatory requirements achieving rights and corporate responsibility into

Compliant environment Salubris strictly prohibits standardized and transparent

daily operations and strictly abides by

all forms of illegal employment and operations. laws and regulations. The Company

complies with national laws and maintains a "zero tolerance" stance Employment Salubris has formulated the towards all forms of discrimination and regulations such as the Labor Law of Management Measures for Prohibiting harassment establishing a comprehensive

Salubris abides by laws the People's Republic of China and Child Labor and Forced Labor resolutely complaint reporting and investigation

regulations and compliance the Labor Contract Law of the People's prohibiting any form of child labor and mechanism to strive for a fair safe

guidelines fully implements Republic of China. The Company has forced labor. At the same time the respectful and healthy work environment.equal employment policies and formulated and implemented the Company has established reporting We adhere to the principle of equality

deeply embodies the concepts Recruitment Management System channels to strengthen supervision. and do not treat employees differently

of diversity equality and serving as the standard and guidance Regarding cases involving child labor based on factors such as place of birth

inclusion. The Company strives for recruitment work. Within the and forced labor upon verification race socioeconomic status nationality

to maintain a positive healthy recruitment management system we employment is terminated immediately hometown religion age disability

standardized orderly and establish diverse recruitment channels victims are provided with assistance gender marital status pregnancy sexual

vibrant workplace ecosystem and incorporate non-discrimination and responsible individuals will face orientation or union affiliation. Meanwhile

creating harmonious and stable as a recruitment requirement building demotion dismissal fines or legal the Company strictly implements national

labor relations. a scientifically grounded selection accountability based on the severity of regulations on working hours overtime

mechanism establishing standardized the circumstances. During the reporting and leave to protect employees’ rights

execution standards and always period no violations such as forced labor and build regulated harmonious and

adhering to the core principles of or child labor occurred at Salubris. sustainable employment relations.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 43

Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety

2025 Salubris Employee Employment Data

Indicator Unit 2025

Total Employees persons 4087

Male persons 2114

By Gender

Female persons 1973

30 years old and below (inclusive) persons 1171

By Age Group 30-50 years old (inclusive of 50 exclusive of 30) persons 2751

Over 50 years old (exclusive of 50) persons 165

Doctoral Degree or Above persons 68

Master's Degree persons 427

By Education Level

Bachelor's Degree persons 1861

Associate Degree and Below persons 1731

General Employees persons 3632

By Job Level Middle Management persons 439

Senior Management persons 16

Mainland China persons 4055

By Region

Hong Kong Macao Taiwan and Overseas persons 32

Han Chinese persons 3834

By Race/Ethnicity Ethnic Minorities persons 215

Overseas Employees persons 38

Production persons 1154

Technical persons 827

By Profession

Sales persons 1698

General Administration persons 408

Full-time Employees persons 3940

By Employment Type

Non Full-time Employees persons 147

Females in Grassroots Management persons 117

Females in Middle Management persons 115

Employee Diversity Females in Senior Management persons 5

Females in STEM-related Positions persons 698

Females in Revenue-generating Management Positions persons 138Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 44

Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety

Indicator Unit 2025

Total New Hires persons 1053

Male persons 501

Female persons 552

New Recruitment

30 years old and below (inclusive) persons 526

30-50 years old (inclusive of 50 exclusive of 30) persons 521

Over 50 years old (exclusive of 50) persons 6

2025 Salubris Employee Turnover Rate

Indicator Unit 2025

Turnover Rate % 16

Male % 17

Turnover Rate By Gender

Female % 15

30 years old and below (inclusive) % 23

Turnover Rate By Age 30-50 years old (including 50 excluding 30) % 13

Above 50 years old (excluding 50) % 13

Mainland China % 16

Turnover Rate By Region

Hong Kong Macao Taiwan and Overseas % 0

General Employees % 16

Turnover Rate By Job Level Middle Management % 13

Senior Management % 0Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 45

Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety

Empowering Employee Growth During the reporting period

To develop a high-quality talent development ecosystem the Company has

established a systematic talent cultivation system and unobstructed career The Company achieved a

development pathways. This creates a tiered workforce that supports organizational training coverage rate of

strategy not only providing high-quality talent supply for business growth but

also comprehensively empowering employees' capability leaps and career

advancements. 100%

Systematic Training System training. Based on organizational and employee training needs surveys the Company formulates annual training plans

Salubris consistently places talent for each level and establishes a training mechanism combining "Internal Training for Foundation" and "External Training

cultivation at the core of its corporate for Innovation."

development strategy. To standardize Furthermore the Company adopts a blended training model integrating online and offline approaches building the

the training management process the "Xin Academy" online platform that covers all enterprise learning scenarios and supports convenient learning. Platform

Company has formulated and refined courses cover multiple directions including management leadership various professional skills and general literacy.the Company Training Management Currently the platform hosts over 5000 courses with employees averaging 14.5 annual online learning hours. Leveraging

System constructing a scientific and the learning platform the Company continues to conduct various thematic activities such as leadership and AI

systematic training framework that initiatives forming an integrated "Learn-Explore-Practice" model. During the reporting period the Company achieved a

clarifies requirements and standards for training coverage rate of 100%.various types of training. Simultaneously

through regular assessment of training

outcomes the Company continuously

optimizes the talent cultivation

mechanism to ensure the sustained

enhancement of training value.The Company has built a talent

cultivation system centered on

career development pathways.By implementing hierarchical and

categorized management this system

covers three levels of standards: the

Company subsidiaries/branches

and departments. Training content

encompasses multiple categories

including general competency training

specialized training and onboarding Xin Academy Thematic TrainingOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 46

Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety

2025 Salubris Employee Training Data

Indicator Unit 2025

Percentage of Employees Trained % 100

Male persons 2114

Number of Employees Trained by Gender

Female persons 1973

Male % 100

Percentage of Employees Trained by Gender

Female % 100

General Employees persons 3632

Number of Employees Trained by Job Level Middle Management persons 439

Senior Management persons 16

General Employees % 100

Percentage of Employees Trained by Job

Middle Management % 100

Level

Senior Management % 100

Total Annual Training Hours hours 240296

Average Training Hours per Employee hours 59

Male hours 62

Average Training Hours by Gender

Female hours 56

General Employees hours 59

Average Training Hours by Job Level Middle Management hours 57

Senior Management hours 18

Number of Employees Under Performance Appraisal or Career Development Assessment9 persons 3651

Percentage of Employees Under Performance Appraisal or Career Development Assessment9 % 90

9 Part-time outsourced and overseas employees are excluded; other employees who due to reasons such as recent onboarding do not fall within the current appraisal period are also not included.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 47

Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety

Unobstructed Career Development Pathways Employee Career Development Pathways

Based on its actual operational conditions and employees' career development

plans Salubris has formulated the Employee Career Development Management Leadership Training

Measures and the Job System Management Measures. Accordingly the Company The Company has launched tiered programs such as the "Xin Class" "Li

establishes different job levels grades ranks and job sequences. For R&D Class " and "Tai Class" leadership tracks to precisely enhance management

Production and other sequences qualification standards are set according to capabilities for employees at different levels.job grades while the Management sequence sets management competency

standards according to job layers. This clarifies employee capability and behavioral

requirements to help employees clarify goals and promote career development. Professional Competency Training

Salubris builds a systematic talent development system taking the dual channels The Company adopts differentiated empowerment strategies customizing

of "Management" and "Professional" as the horizontal core and vertically exclusive professional growth paths for employees. Through the "Three-Level"

establishing promotion pathways from low to high job levels grades and training system this initiative enables senior talent to rapidly transition into

rank. Relying on the online platform "Xin Academy" and offline training projects professional roles.comprehensive support is provided. Employees can flexibly choose promotion

within the same channel cross-channel development or lateral transfers to New Talent Training

broaden their professional scope enhance comprehensive capabilities and The Company has established a three-year structured development

person-job fit thereby optimizing performance. program for campus recruitment management trainees to build their

professional capabilities and support their long-term career development.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 48

Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety

Unlocking Employee Potential organizational efficiency and employee personal development levels.The Company continuously improves the medium-to-long-term incentive

The Company continuously improves the closed-loop performance management system and orderly implements employee equity incentive arrangements deeply

mechanism aligning individual performance and contributions with the Company’s linking them with annual performance results to improve the precision of the

long-term strategic objectives. It establishes a long-term link between core talent incentive mechanism and strengthen the synergy matching between incentive

incentives and the Company's long-term development strengthening the internal orientation and strategic goals. Through building a diversified reward system and

drive for sustainable organizational development. Meanwhile the Company is unobstructed career development pathways the Company consolidates talent

committed to building an inclusive and open workplace ecosystem streamlining introduction cultivation incentive and retention capabilities strengthens core team

channels for employees to express concerns improving feedback response cohesion and provides talent support for the enterprise's sustainable operation

mechanisms and effectively safeguarding employees' legitimate rights and and development.interests.Diversified Incentives Employee Care

Salubris strictly complies with laws and regulations such as the Social Insurance Salubris strictly complies with national and local labor laws and regulations

Law of the People's Republic of China the Company Law of the People's Republic formulates the Attendance and Leave Management Measures and continuously

of China and the Securities Law of the People's Republic of China and formulates improves non-compensation welfare guarantee mechanisms. The Company

internal regulations such as the Compensation Management Measures and the systematically builds an employee care system covering health care welfare

Performance Management Measures. The Company is committed to building a support and work-life balance focusing on creating a reassuring warm workplace

fair transparent and market-competitive compensation and benefits system. By environment with a strong sense of belonging.continuously advancing the standardization and normalization of its compensation

system the Company has established a salary structure centered on fixed salary

performance bonuses and supplementary allowances. It has also introduced

supplementary benefit programs covering holiday allowances commercial 2025 Salubris Employee Benefits

insurance and other items to effectively safeguard employees’ rights and

interests. The Company binds employees' individual performance and job value Provide employees with various personal leave including paid annual leave welfare

to the Company's long-term development ensuring incentive effectiveness while leave paid sick leave maternity leave paternity leave and nursing leave along with

considering the guarantee function thereby stimulating organizational vitality health checkups supporting employees in reasonably balancing work and life;

comprehensively.Regularly host diverse cultural sports and festival-themed activities and provide

The Company has established and implemented a performance management holiday greetings birthday perks and customized uniforms at key occasions to

system covering all employees and departments standardizing the management foster team cohesion.of individual and departmental performance goal commitment forms and their

decomposition processes to ensure the clarity and traceability of goal setting. Provide localized amenities such as talent apartments staff dormitories employee

The Company initiates team and individual performance assessment work cafeterias recreational facilities and commuter shuttles to significantly enhance

formulating performance goal commitment forms and process flowcharts to daily convenience and off-work quality of life.ensure the orderly implementation of assessment work. In addition the Company Offer annual health screenings and an employee mutual aid program (covering

attaches great importance to the performance feedback and improvement links hospitalization critical illness and accidents) alongside dedicated support and

regularly conducting performance interviews and formulating detailed feedback condolence initiatives for critical illness maternity or the loss of an immediate family

and improvement plans. This forms a management closed loop of "Goal Setting member.– Assessment Execution – Feedback Improvement" to continuously improveOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 49

Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety

Employee Communication and Satisfaction

Salubris respects individual differences and diverse backgrounds of employees assisting corporate culture construction and business strategy implementation

and is committed to creating an equal and inclusive internal communication and strengthening team cohesion. The Company has now formally included the

atmosphere. It establishes multi-level institutionalized employee communication performance appeal process in the performance management system supporting

and democratic participation mechanisms fully safeguarding employees' rights and perfecting standardized forms for performance appeals and performance

to know participate and express. This guides employees to deeply participate in interviews further completing the closed loop of employee communication

enterprise construction ensuring every employee's voice is heard and demands feedback and rights protection.are handled fairly and timely. To clarify organizational development direction Salubris conducts annual

The Company builds a three-dimensional communication channel combining satisfaction surveys for all employees covering dimensions such as welfare

online and offline links supplementing real-name and anonymous methods. policies compensation performance occupational health etc. to comprehensively

Through OA systems collaborative forms suggestion boxes dedicated feedback gain insights into core advantages of organizational management and key areas

emails and other channels employees are supported to conveniently and urgently needing improvement in the future. Based on survey results the Company

efficiently express views and feedback demands regarding process optimization quickly implements optimization measures and plans annual improvement

training experience system iteration daily management etc. The Company strategies effectively absorbing employee feedback continuously improving the

continuously listens to employees' voices and responds to reasonable suggestions working environment and creating an excellent organizational atmosphere.in time promoting collaboration among employees from different backgroundsOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 50

Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety

Ensuring Health and Safety

Salubris adheres to the occupational health and safety policy of "people-oriented ensuring safety production" regarding the health and safety of employees and

stakeholders as the cornerstone of the company's sustainable and robust development. Guided by the occupational health and safety objectives of "zero work-related

fatalities and injuries and zero occupational disease cases" we deeply integrate occupational health and safety management into the full process of R&D production and

operations continuously fostering an inherently safe healthy and harmonious working environment.Safety Production

| Work Safety Governance

Structure

Salubris strictly complies with laws and

regulations such as the Work Safety Law

of the People's Republic of China and

has formulated internal policies including

the HSE Management Measures and the

Environmental Occupational Health and

Safety Management System Manual. A

Group Work Safety Committee has been

established as the central decision-making

body with each organization establishing

its own sub-committee. Dedicated safety

management departments have been set up

and staffed with full-time safety professionals.This comprehensive safety governance

framework covers all company premises and

extends to all full-time employees part-time

employees contractors suppliers and other

relevant stakeholders. | Work Safety Management System

| Accountability Mechanism The Company has built a comprehensive safety management system covering risk control emergency response

compliance review and all-staff communication effectively achieving dynamic risk prevention and control and efficient

We have established a management- emergency response of unexpected incidents ensuring continued compliant operation. We continuously advance the

level safety accountability mechanism digitalization of HSE management by developing a unified information platform that integrates core modules such as

incorporating safety and health performance risk grading and control hazard identification and rectification work permit management safety training occupational

indicators into the performance appraisal health records and contractor management. Relying on a unified data foundation the system achieves standardized

and compensation-linked system for collection of safety indicators improving data completeness accuracy and auditability.management personnel thereby reinforcing During the reporting period the Company's work safety management system received external recognition with the

primary safety responsibilities at all levels. Bao'an Shandong and Suzhou plants all obtaining Level 3 Work Safety Standardization certification.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 51

Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety

Salubris Safety Management Mechanism

■ Conduct hazard identification at work sites quarterly establishing risk graded control ledgers; organize a comprehensive risk re-evaluation

Safety Risk Assessment

annually to ensure dynamic effectiveness of risk identification.■ Conduct comprehensive reviews of health and safety management situations at all operating locations semi-annually forming HSE supervision

Safety Compliance Review

reports and HSE dynamic review reports ensuring all operating locations operate safely and compliantly.■ Hold annual work safety committee meetings to ensure deep participation of management layers union representatives and employee

representatives in safety matter decision-making and discussion.■ Each branch convenes regular monthly work safety committee meetings chaired by the head of the respective institution and attended by

Regular Communication

department heads from safety management production operations equipment maintenance and other relevant functions alongside employee

representatives. Through this standardized monthly communication mechanism safety directives are promptly cascaded to frontline teams

ensuring the effective execution of safety decisions and corrective action plans.■ Launch HSE information management platform supporting employees to report unsafe behaviors accident hazards and near-miss events

Digital Enabled Management

rewarding those who actively report.■ Strictly implement occupational health and safety control requirements during contractor entry and cooperation signing audit partner safety

Contractor Safety Requirements qualifications and include safety control clauses in cooperation contracts. Carry out comprehensive safety training for all contractor personnel

with a training coverage rate of 100% for contractors.Salubris Safety Production Indicators

| Emergency Management Indicator Unit 2025

The Company attaches great importance to emergency management Lost Workdays Due to Work Injuries days 97

formulating the Accident Reporting and Investigation Disposal Procedures incidents per 200000

clarifying comprehensive emergency plans and special disposal schemes Total Recordable Incident Rate (TRIR) working hours 0.0970

for fire mechanical injury chemical leakage etc. We regularly organize Lost Time Injury Rate (LTIR) incidents per 200000 0.0970

emergency drills for scenarios such as fire electric shock hazardous working hours

chemicals leakage poisoning and suffocation completely retaining drill Near-miss Report Rate incidents per 200000 98

records and rectification tracking archives continuously improving the working hours

capabilities of emergency response. Hazard Rectification Rate % 99.66

Contractor Lost Time Injury Accident Events incidents 0

The Company sets the occupational health and safety goal of "zero casualty Work Injury Insurance Investment Amount RMB 10000 301

accidents zero occupational disease" and sets quantitative indicators Work Injury Insurance Coverage 10 persons 3936

around it to promote goal implementation. During the reporting period no

serious work-related casualties or occupational diseases occurred among

both employees and contractors with 97 workdays lost due to work-related

injuries. The number and rate of work-related fatalities were zero in 2023

2024 and 2025. 10 Retired rehired employees and interns are not covered by work-related injury insurance; the Company separately

purchases accident insurance for them.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 52

Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety

Salubris Occupational Health and Safety Training Indicators

Workplace Safety Training

Indicator Unit 2025

The Company has formulated an

annual occupational health and Total Person-Times of Occupational Health and Safety Training person-Times 35392

safety (OHS) training plan delivering

routine safety training to internal

employees contractors and suppliers. Total Duration of Occupational Health and Safety Training hours 44770

The training covers safe work

practices and the management of Total Sessions of Occupational Health and Safety Training times 861

high-risk operations including hot

work. For newly hired employees in Total Sessions of Occupational Health and Safety Training Conducted for Contractors times 158

production positions the Company

strictly implements the three-level Covered Number of Contractors for Occupational Health and Safety Training persons 1754

safety education—factory level

workshop/department level and Coverage Rate of Occupational Health and Safety Training for Contractors % 100

team level—to ensure that employees

master job-specific risk identification Total Training Hours for Contractors hours 978

and emergency response skills before

working independently. Certification Rate for Special Operations Personnel % 100

| Safety Production Cultural Activities

Salubris continuously promotes safety production culture construction creating an

all-staff participatory safety culture atmosphere through diversified publicity activities.The Company regularly holds themed activities such as Safety Production Month and Fire

Prevention Month publishes the Salubris HSE Culture Knowledge Manual and the Employee

HSE Manual pushes safety concepts via safety culture columns thematic posters and

new media platforms; synchronously carries out publicity of "Top Ten Safety Concepts" and

"Top Ten Life-Saving Rules" organizes safety knowledge competitions and emergency skill

drills strengthening employee safety awareness and emergency response capabilities.The Company establishes a positive incentive mechanism annually selecting "HSE Annual

Figures" "Safety Guardians" and other advanced models encouraging employees to

actively report unsafe behaviors and near-miss events organize HSE-themed expert

activities safety promoting management transformation from passive response to active

prevention effectively safeguarding employee life safety and production operation stability.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 53

Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety

Salubris Occupational Health Management Measures

Occupational Health Occupational Health Examinations

Salubris strictly complies with

■ Pre-employment occupational health examination: Newly recruited personnel and transferred personnel must pass occupational health

laws and regulations such as checks before engaging in jobs contacting occupational hazard factors;

the Law of the People's Republic

■ Periodic occupational health examination: Regularly organize occupational health checks for employees exposed to occupational hazards

of China on the Prevention annually;

and Control of Occupational

■ Abnormal handling: Transfer employees discovering occupational contraindications or occupational-related health damage from original

Diseases. The Company has posts and properly arrange them inform them truthfully and require re-examination or medical observation/treatment according to

established and implemented inspection institution requirements.internal policies including the

Occupational Disease Hazard Hazard Factor Identification and Monitoring

Responsibility Prevention Labor Protection Equipment Management

System the Occupational

Protective Equipment ■ Determine and identify dust noise high temperature toxic ■ Regularly distribute labor protection equipment for free.Management System the substances and other hazard factors and points in workplaces Establish regular quality inspection and maintenance systems

Occupational Hazard Monitoring conducting regular detection and evaluation according to for special protective equipment such as safety helmets

and Evaluation Management occupational hygiene management standards. insulating protective equipment and gas masks; prohibit use

System and the Occupational of unqualified or invalid equipment.Hazard Accident Handling and

Reporting System. The Company Job-specific Training Implementation of the "Three Simultaneities" system

has also built a comprehensive

employee health protection

■ Employees in occupational disease risk posts participate in ■ Strictly implement the "Three Simultaneities" system for

system covering the full business occupational safety education training for no less than 20 occupational disease prevention facilities in construction

chain to consolidate employees’ hours annually. Training content covers occupational hygiene projects ensuring occupational disease prevention facilities

health defenses and safeguard laws and regulations and standards basic occupational are designed constructed and put into production and use

employees’ occupational health hygiene knowledge correct use and maintenance of simultaneously with main projects.and rights. protective equipment and personal protective equipment

emergency rescue measures and basic skills etc.In 2025 the regular monitoring coverage

for occupational hazard factors across all

workplaces reached 100%. Both training and

occupational health examination coverage 0 100% 100% 100%

for the 964 employees in hazard-risk positions occupational regular monitoring training coverage for occupational health

stood at 100%. With no occupational hazard disease incidents coverage for occupational employees in hazard- examination coverage

incidents or suspected cases reported the hazard factors across all risk positions for employees in

Company successfully achieved a "zero workplaces hazard-risk positions

occurrence" of occupational diseases.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 54

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

04

G reening the Future Fostering

Ecological Harmony

Salubris always regards green

development as one of the long-

term strategic drivers for enterprise

transformation comprehensively

promoting low-carbon transformation

and ecological environmental protection.Through gradually strengthening

climate risk management improving the

environmental management system

enhancing resource utilization efficiency

and deepening circular economy

practices in packaging links while

promoting high-quality development

of the pharmaceutical industry the

Company actively fulfills its environmental

RMB 28.63 million responsibilities jointly building a

sustainable future of harmony between

total expenditure on environmental humans and nature.management

Multiple sites including Bao'an Factory

0 Daya Bay Factory Pingshan Factory have obtained ISO 14001 Environmental

major accidents involving violations Management System certification.of environmental laws or major Bao'an Factory has passed ISO 50001

environmental pollution incidents Energy Management System certification.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 55

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

Responding to

Climate Change

Salubris recognizes the impact of

climate change on global public

health and the pharmaceutical

industry integrating climate action into

corporate strategic decision-making.The Company has established a

comprehensive climate management

framework aligned with four core

pillars: governance strategy risk

management and metrics and

targets. Through this framework the

Company is committed to reducing its

operational carbon footprint driving

green transformation and supporting

global climate action.Salubris Climate Change Governance Structure and Responsibilities

Governance

Board of Directors

Salubris has established a three-

level climate governance framework ■ As the highest decision-making body responsible for approving climate-related strategies

comprising the Board of Directors Governance supervising the management effectiveness of climate risks and opportunities and regularly

Production Center HSE Management Level reviewing the achievement of climate goals.Group and Business Departments

and Functional Departments. The Production Center HSE Management Group

Board of Directors serves as the

highest-level governing body ■ As the management body responsible for formulating climate strategies goals and plans

providing strategic oversight and Management supervising their implementation evaluating major climate risks and opportunities and

guidance for all climate-related Level submitting them to the Board of Directors for deliberation.initiatives. Through clearly defining

responsibilities and powers at each Business Departments and Functional Departments

level we strengthen climate change

■

management. As the execution body responsible for implementation of climate management including

Executive formulating action plans promoting emission reduction projects monitoring and reporting

Level climate performance and regularly reporting progress.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 56

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

Strategy

Salubris attaches importance to short- medium- and long-term physical risks and transition risks brought by climate change establishing a robust mechanism for risk

assessment and opportunity identification formulating forward-looking countermeasures for potential risks.Climate-Related Risk Identification

Risk Type Risk Description Countermeasure Actions Impact Potential Period Financial Impact

■ Establish regular facility inspection mechanisms strengthen key equipment

Extreme weather events

reinforcement and drainage system maintenance;

caused by climate Increase in

Acute Risk ■ Improve extreme weather emergency plans and conduct regular drills; Short-term

change (e.g. floods

■ Optimize supply chain layout implement multi-source supply strategies establish operating costs

typhoons)

Physical key material strategic reserves enhance supply chain resilience.Risk

Long-term climate ■ Adopt efficient intelligent air conditioning systems achieving precise indoor

change causing temperature control mitigating external climate fluctuations' impact on Medium/ Increase in

Chronic Risk

continuous impacts (e.g. operational stability; Long-term operating costs

extreme heat droughts) ■ Deepen water resource recycling technologies promote water-saving processes.Policy and ■ Establish policy regulation dynamic tracking mechanisms review compliance Medium/ Increase in

Carbon pricing increases

Legal Risk status actively seek green credit tax incentives and other policy support; Long-term operating costs

Low-carbon energy- ■ Continuously deepen the transformation and upgrading of low-carbon energy-

Technology Medium/ Increase in

saving technology R&D saving technologies to reduce carbon emissions across all links including R&D

Risk Long-term

and transformation trends production and the supply chain. R&D costs

■ Continuously deepen green procurement and low-carbon supply chain

Transition

Raw material cost development advance raw material cost control and energy-saving upgrades Medium/ Increase in

Risk Market Risk

increases across the supply chain and reduce the procurement and logistics costs of core Long-term operating costs

raw materials.■ Strengthen the comprehensiveness and accuracy of climate information

Stakeholder attention disclosure continuously disclose carbon emission data and monitor emission

Reputation Medium/ Decrease in

to company climate reduction goal progress;

Risk Long-term

response performance ■ Regularly communicate with investors timely reply to their opinions and revenue

suggestions on company climate change-related work.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 57

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

Climate-Related Risk Identification

Risk Type Risk Description Countermeasure Actions Impact Potential Period Financial Impact

Resource Efficiency

Resource ■ Optimize production process flows reduce unit product resource consumption thereby Medium/ Decrease in

Improvement

Efficiency reducing energy and water procurement costs improving overall operational efficiency. Long-term operating costs

Opportunities

■ Increase the proportion of renewable energy in total energy structure reduce

Renewable Short/

Clean Energy dependence on fossil fuels avoid traditional energy price fluctuation risks; Decrease in

Opportunity Energy Utilization Medium-

Utilization simultaneously utilize government subsidy policies for green energy projects reducing operating costs

Opportunities term

construction and operating costs of clean energy facilities.■ Conform to global market demand for low-carbon products meet international

Industry Market Expansion Medium/

emerging markets' "green medicine" access standards participate in global sustainable Increase in revenue

Development Opportunities Long-term

medical initiatives enhance market share and brand international influence.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 58

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

Risk Management

Salubris integrates climate change risk Climate Change Risk Management Process

management into the Company's comprehensive

risk management framework establishing a full-

process closed-loop mechanism covering risk Regularly identify potential climate-related risks integrating climate

identification assessment and response. Through factors into existing risk control systems.strengthening cross-departmental collaboration Risk Identification

and implementing board supervision functions it

achieves comprehensive management of climate- Grade and classify risk events according to severity and likelihood

related risks and opportunities. compiling risk reports to provide data support for subsequent

management measure formulation.Risk Assessment

Metrics and Targets

To supervise and promote the Company's climate Formulate various emergency plans and organize drills regularly

change work Salubris sets a series of carbon emission- tracking the implementation effectiveness of climate change risk and

related goals clarifying emission reduction paths Risk Response opportunity countermeasures.through quantitative management building a

sustainable low-carbon operating framework.

2025 Salubris GHG Emission Data

41% Indicator Unit 2025

The Company has established a carbon Scope 1 Greenhouse Gas Emissions

12 tCO2e 9897

reduction target: using 202411 as the baseline Scope 2 Greenhouse Gas Emissions 13 tCO

year the Scope 1 and Scope 2 greenhouse 2

e 54689

gas emission intensity will be reduced by Total Greenhouse Gas Emissions tCO2e 64586

41% by 2030.

Greenhouse Gas Emission Intensity tCO2e / RMB million of revenue 14.84

6.7%

In 2025 the Scope 1 and Scope 2 11 In 2024 our Scope 1 and Scope 2 greenhouse gas emission intensity was 15.9 tCO2e / RMB million of revenue.greenhouse gas emission intensity 12 Scope 1 greenhouse gas emissions primarily arise from the direct combustion of fuels such as gasoline diesel and natural gas. The Scope 1 emissions were quantified in

decreased by 6.7% compared with the accordance with the 2006 IPCC Guidelines for National Greenhouse Gas Inventories published by the Intergovernmental Panel on Climate Change (IPCC).baseline year. 13 Scope 2 greenhouse gas emissions mainly originate from purchased electricity and purchased heat. The electricity emission factor is selected from the Announcement

on the Release of 2022 Electricity Carbon Dioxide Emission Factors jointly issued by the Ministry of Ecology and Environment of the People's Republic of China and the

National Bureau of Statistics. The steam emission factor is calculated on a comprehensive basis in accordance with the Guidelines for Accounting and Reporting of

Greenhouse Gas Emissions from Enterprises in Other Industrial Sectors (Trial) and the 2006 IPCC Guidelines for National Greenhouse Gas Inventories.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 59

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

Strengthening Environmental Management

Salubris strictly complies with national environmental The Company has formulated the Emergency

protection regulations formulating and improving Response Plan for Sudden Environmental

an environmental management system mainly Incidents targeting environmental risks

composed of the Environmental Protection During the reporting period that may arise in production and operation In 2025

Management System and the HSE System processes to effectively prevent and minimize

28.63 no major accidents Management Manual. We uphold the environmental environmental pollution and losses caused violating environmental policy of "Harmonious Environment Achieving RMB million by sudden environmental incidents. In laws and regulations and

Sustainable Development" aiming to achieve accordance with the emergency plan we major environmental

"zero environmental pollution accidents." During total expenditure regularly conduct environmental emergency

on environmental pollution accidents the reporting period our total environmental drills to ensure timely reporting rapid occurred.management investment was RMB 28.63 million management response and efficient disposal in the event of

mainly including expenditures on operating waste environmental pollution incidents.disposal upgrading and maintaining environmental

protection equipment etc.The Company builds an environmental management Case Acidic Wastewater spill Emergency Response Simulation Drill

governance architecture composed of HSE Production

Center and each factory ensuring environmental

management operates in a standardized manner and is To improve hazardous waste operators'

executed effectively. HSE Production Center is responsible emergency response capabilities for

for overall management and supervisory deliberation of hazardous waste leaks in October 2025

company environmental matters regularly evaluating Salubris organized a simulated acidic

goal execution progress ensuring environmental wastewater spill emergency response

management remains coordinated with the Company's drill. The drill set a scenario where

overall development strategy. Each factory is responsible an environmental specialist spilled

for implementing specific environmental protection wastewater en route from transporting

measures ensuring compliance throughout the acidic wastewater from the laboratory to

production and operation process. the hazardous waste warehouse due to

To continuously improve environmental management lack of guardrails on the transport cart and

practices the Company strictly adheres to ISO 14001 overly sharp turning. On-site personnel

standards continuously improving the environmental immediately activated the emergency

management system. As of the end of the reporting plan for disposal. After the drill ended

period 5 office and production sites including environmental engineers summarized and

the Bao'an Factory and the Daya Bay Factory Environmental Management provided corrective action guidance on Acidic Wastewater spill

have obtained GB/T 24001-2016 / ISO 14001:2015 System Certification issues identified during the drill process. Emergency Response Drill Site

Environmental Management System certification. CertificateOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 60

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

Practicing Resource Conservation

Salubris values resource management improving resource utilization efficiency

through optimized resource allocation and full-process management. Meanwhile

we actively practice the circular economy concept committed to building a

green and sustainable operation model to achieve coordinated development of

economic and environmental benefits.Energy Management

Salubris regulates and implements

energy management according

to systems such as the Energy

Management Manual and the

Energy Management Policy Goals

Scheme Control Procedures.The Company formulates

special energy monitoring plans

continuously summarizing

data monthly and conducting

comparative analysis ensuring

real-time rectification when

abnormalities are detected. In

2025 Bao'an Factory obtained ISO

50001 energy management system

certification.Energy Management System

Certification CertificateOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 61

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

Energy Management Measures

■ Optimize Blower Systems: Assess environmental blower air volume

requirements replacing original blowers with low-power high-efficiency

equipment saving approximately 130000 kWh of electricity annually.■ Upgrade Sterile Workshop Refrigeration Systems: Replace sterile

workshop chillers improving refrigeration energy efficiency ratios

effectively reducing electricity consumption required to maintain sterile

environments saving approximately 480000 kWh of electricity annually.■ Strengthen High-Voltage Electrical O&M: Entrust third parties to conduct

preventive testing and maintenance for factory transformers and other

high-voltage electrical equipment improving electricity usage safety

while reducing power loss.■ Deepen Energy Management Digitalization: Implement energy

management systems achieving online collection of water electricity

gas and steam data promoting management model transformation

from manual statistics to trend analysis and alarm tracing.■ Promote Fuel Structure Optimization: Introduce biogas to replace natural

gas in RTO (Regenerative Thermal Oxidizer) systems reducing fossil

energy consumption and lowering carbon emissions.■ Boiler Waste Heat Recovery: Recover steam condensate and boiler flue

gas waste heat to boilers achieving resource recycling and reducing

resource waste.■ Chiller Unit Update and Transformation: Eliminate screw chiller units use

magnetically levitated chillers with high refrigeration efficiency reducing

electricity consumption.■ Optimize Cooling System Operation Modes: Transform cooling systems

from constant frequency operation to on-demand automated control

reducing cooling losses and lowering electricity consumption.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 62

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

Case Energy Monitoring and Management System Project | Clean Energy Usage As of December 31 2025

The Company explores the broader

application of green energy in

manufacturing processes promoting 3.39 million kWh

Salubris launched the energy monitoring and management system factory clean energy retrofitting. In July

2024 distributed photovoltaic power cumulative clean electricity project aiming to replace traditional manual meter-reading

processes. Building upon existing systems the project established an generation projects were successively

generated by the Company's PV

projects

online monitoring platform for the automated collection centralized completed and connected to the

management and intelligent analysis of electricity steam and grid at the Daya Bay and Huizhou

other energy data. The project has completed the connection and factories. The Company’s PV projects 1820 tonnes

commissioning of 38 electricity meters and 16 steam meters with data make use of factory rooftops to install

upload success rates reaching 99.8%. the photovoltaic system under a self-

reducing carbon dioxide emissions

generation and self-consumption by approximately

The project improved energy consumption data accuracy from 91% model with generated clean electricity

to 99.6% reducing manual recording errors and omissions. Abnormal prioritized for factory production and

alarm response times shortened from 4.5 hours to 12 minutes; during supporting facilities. Projects are

trial operation energy waste losses of approximately RMB 27000 equipped with intelligent photovoltaic 50%

were successfully avoided effectively reducing unnecessary energy monitoring systems that enable real- Currently the Company has set clear

consumption. time monitoring of power generation energy consumption goals: with 202414

efficiency and equipment operation as the base year energy consumption

status ensuring stable and safe intensity will decrease by 50% by 2023.operation of the stations.Energy Usage

Indicator Unit 2025

Natural Gas m3 4466810

Direct Energy

Consumption Gasoline tonnes 21

Diesel tonnes 3

Purchased

Indirect Energy Electricity MWh 73503

Consumption

Purchased Heat GJ 138615

Comprehensive Energy Consumption tonnes of standard coal equivalent 19739

Comprehensive Energy Consumption tonnes of standard coal

Intensity equivalent /RMB million of revenue 4.53

Energy Monitoring Management System

14 In 2024 our energy use intensity was 5.2 tonnes of standard coal per million RMB of revenue.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 63

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

Water Resource Management

Salubris strictly complies with laws and regulations such as the Water Law of the People's Republic of China and Water Resource Management Measures

the Water Pollution Prevention and Control Law of the People's Republic of China systematically advancing water

conservation management and water resource protection work. Following national standards the Company regularly ■ Optimize Injection Water Systems: Under

conducts water risk monitoring and assessment. This process identifies potential risks spanning from water source strict guarantee of water quality safety

supply and production processes to final discharge allowing us to formulate differentiated strategies and significantly streamline and optimize factory injection

improve water resource risk management capabilities. The Company takes "water resource recycling rate" and "total water processes reducing consumption

water consumption" as core control goals continuously deepening efficient water resource utilization.estimated to save approximately 2418

tonnes of steam annually.■ Upgrade Automated Control Systems:

Complete automatic control upgrades for

12 circulating water pumps and 10 cooling

towers replacing elevated manual valves

throughout the plant with electric automatic

valves and implementing load automatic

regulation transformations for three water

systems achieving precise water supply and

high-efficiency energy saving.■ Implement Water Resource Recycling:

Establish concentrated water and chilled

water recovery monitoring and tracking

mechanisms and promote reuse effectively

reducing fresh water consumption forming

stable water-saving benefits.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 64

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

Case Public System Automatic Control Energy Saving Upgrade Project

In June 2025 Shandong Factory completed

intelligent transformation of five major

public systems in the factory area. The

project implemented automatic control for

12 circulating water pumps and 10 cooling

towers upgraded manual valves to electric

valves achieved automatic load regulation

and chiller interlock control for three water

systems and integrated them into a unified

access to centralized monitoring platform.The project achieved significant results

realizing a comprehensive energy saving

rate of 32% saving approximately 276000

kWh of electricity annually reducing

carbon emissions by approximately 148.1

tonnes and saving energy consumption

costs of nearly RMB 200000 achieving

dual improvements in environmental and Public System Intelligent

economic benefits. Transformation

Water Resource Usage15

Indicator Unit 2025

Total Water Consumption tonnes 848190

tonnes/RMB million of

Total Water Intensity 194.87

revenue

Water Withdrawal Volume tonnes 779914

Water Consumption Volume tonnes 191819

Water Resource Recycling Volume tonnes 68276

Industrial Water Reuse Rate % 8.75

15 Total Water Consumption=Water Withdrawal Volume +Water Resource Recycling Volume Water Withdrawal

Volume=Water Consumption Volume+Total Wastewater DischargeOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 65

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

Circular Economy

Salubris integrates green packaging concepts into its product full-lifecycle

management and is committed to building a sustainable packaging system

through source reduction material innovation and closed-loop recycling thereby Case Reducing Inner Packaging Waste

comprehensively promoting intensive resource utilization and circular regeneration.To effectively reduce production cost waste caused by inner packaging

waste in January 2025 Shandong Salubris carried out a special research

project on reducing inner packaging waste. The project analyzed waste

causes in packaging material usage processes and formulated targeted

improvement measures accordingly. By optimizing management

strategies the Company extended the validity period of sterilized packaging

materials from 24 hours to 48 hours and adjusted the sterilization limit for

unused packaging materials from "single-use only" to "double-sterilization

permitted." Practice verification confirmed significant results. Practical

verification has demonstrated significant effectiveness of these measures.The Company compiled and published management regulations such

as "Sterilized Equipment and Items Management Procedures" to provide

guidance for subsequent standardized management.During the Reporting

Packaging Material Management Measures

■ Upgrade Cold Chain Packaging Specifications: Replace small cold

chain packaging with large-capacity versions improving single-trip 3169 tonnes

transportation efficiency; period packaging material usage

■ Promote Circular Replacement Solutions: Replace traditional

cardboard boxes and fiber drums with reusable bulk bags reducing

disposable packaging material consumption and waste generation; 0.73 tonnes/RMB million

of revenue

■ Adjust Raw Material Packaging Specifications: Adjust product

packaging specifications from 5kg/piece and 10kg/piece to 15kg/piece packaging material usage

and 20kg/piece reducing PE bag usage.intensityOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 66

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

Promoting Green Case Wastewater Treatment Facility Upgrade and Transformation

Operations

Salubris fully implements green production

concepts in daily operations systematically The Huizhou Factory invested

controlling wastewater waste gas and solid RMB 400000 to purchase a set

waste generated in R&D and manufacturing of MBR membrane filtration

processes effectively reducing the components with a treatment

environmental impacts of operational activities. capacity of 600 tonnes/day to

solve the problem of decreased

treatment efficiency caused by

Wastewater Management aging original MBR membranes

replacing and updating old MBR

Salubris strictly executes water pollutant membranes in the wastewater

emission standards and key pollutant total system further guaranteeing

quantity control requirements designing wastewater treatment effluent

water supply and drainage systems quality.according to the principle of "separation

of clean and dirty water rain and sewage

separation and recycled water usage" Wastewater Treatment Facility Upgrade

establishing sewage outlets in accordance

with regulations ensuring stable and

compliant wastewater discharge. The

Company continuously optimizes wastewater

treatment processes enhancing wastewater Wastewater Discharge

treatment efficiency.In terms of monitoring management Indicator Unit 2025

wastewater discharge relies on a

combination of automatic monitoring routine Total Wastewater Discharge tonnes 588096

patrols and regular external monitoring

perfecting wastewater end monitoring Total Wastewater Pollutant Discharge tonnes 98.46

accurately grasping wastewater discharge

concentration changes timely identifying

potential non-compliance risks ensuring Chemical Oxygen Demand (COD) tonnes 94.82

all factories' wastewater end discharge

fully meets standards. Meanwhile we apply Ammonia Nitrogen tonnes 3.55

on-site high-temperature thermal sterilization

technology effectively killing pathogens and Total Phosphorus tonnes 0.09

reducing environmental risks.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 67

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

Waste Gas Management

Salubris continuously optimizes (LDAR) plans are regularly conducted

atmospheric pollution control and annual third-party airtightness

facilities strengthening the waste checks are commissioned effectively Case Waste Gas Incineration System

gas management system. Classified controlling dispersion risks. In 2025 the

collection and efficient treatment are Company's organized volatile organic

implemented for process waste gases compounds (VOCs) emissions decreased

by approximately 1 tonne compared The Shandong Factory invested RMB ensuring compliant discharge. For

fugitive emissions equipment sealing to 2024 and fugitive VOCs emissions

5.02 million to establish a new set of

is improved Leak Detection and Repair decreased by approximately 3.5 tonnes.Regenerative Thermal Oxidizers (RTO)

with a treatment capacity of 50000

cubic meters/hour further improving

the factory's high-concentration

complex-component organic waste gas

Waste Gas Management Measures governance efficiency solidifying the

foundation for stable waste gas compliant

During the Reporting ■ The Company currently has 3 sets of discharge. After the system entered

RTO (Regenerative Thermal Oxidizers) operation it formed complementarity with existing existing scrubbing processes

and multiple sets of activated carbon governance processes achieving a

adsorption systems. By completing system purification efficiency of over

inspection and transformation of 99% significantly enhancing the factory's Waste Gas

the No. 1 RTO unit overall waste gas comprehensive waste gas governance Incineration System

capabilities.the Company's organized treatment capacity was improved;

volatile organic compounds simultaneously operation strategies

(VOCs) emissions decreased are optimized to improve treatment

by approximately efficiency and reduce VOCs emissions;

Waste Gas Discharge Data1 ■ Strictly implement regular activated tonne carbon replacement systems Indicator Unit 2025

guaranteeing adsorption governance

effects ensuring continuous waste gas Total Waste Gas Discharge m3 1176758474

compared to 2024 and fugitive

VOCs emissions decreased by compliant discharge; Particulate Matter tonnes 1.59

approximately ■ Strengthen supervision and

3.5 maintenance of workshop waste gas

Nitrogen Oxides tonnes 6.97

tonnes. collection and pretreatment facilities

Sulfur Oxides tonnes 0.78

regularly conducting special training

to ensure stable facility operation. Volatile Organic Compounds (VOCs) tonnes 11.93Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 68

Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations

Biodiversity Protection

Salubris strictly complies with the Forest

Waste Management Law of the People's Republic of China

Salubris formulates and improves the Hazardous In 2025 the Company conducted regular targeted the Environmental Impact Assessment

Waste Management System clarifying full- HSE inspections. Through on-site verification of record Law of the People's Republic of China

process control requirements for classification ledgers and inspection of temporary storage facilities and international biodiversity protection

storage and compliant disposal management. the Company comprehensively identified potential initiatives integrating the minimum

The Company adopts a combined mode of hazardous waste risks ensuring that hazardous waste disturbance principle into site selection

"on-site storage" and "entrusted certified third- management strictly complied with national laws and operations and the entire supply chain

party disposal" implementing strict control to regulations and the Company's internal standards lifecycle. In terms of spatial planning all

effectively prevent secondary pollution risks during thereby effectively reinforcing environmental safety company R&D bases and production

disposal processes. safeguards. factories are scientifically sited to avoid natural protected areas and ecological

red line zones ensuring they are far from

biodiversity-sensitive areas to eliminate

destruction of original vegetation and

ecosystems at the source. Meanwhile

During the Reporting we strictly observe ethical standards by

resolutely prohibiting the use of protected

Total non-hazardous Non-hazardous waste Total hazardous Hazardous waste animals in scientific experiments

waste intensity waste intensity and establish rigorous sustainability

evaluation mechanisms in the raw

material procurement process refusing

1264 0.29 4915 1.13 to use rare and endangered plants

tonnes/RMB million of revenue and animals as raw materials and fully tonnes tonnes tonnes/RMB million of revenue transitioning to environmentally friendly

alternative solutions.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 69

Deepening Inclusive Healthcare Building a Better Society Together

05

S erving Society Enriching

Lives

Salubris actively fulfills corporate social

responsibilities continuously improving

medical accessibility delivering

high-quality medical resources to

grassroots and underdeveloped

regions. Meanwhile we carry out

diversified public welfare charity

activities effectively improving

livelihood well-being building a social

value ecosystem

32 RMB 27.1 million 1965 hours

marketed drugs have been Annual total charitable donation Cumulative annual service hours

included in the NRDL amount We Commit:

20000+ 200 7.18 Oriented towards unmet clinical needs RMB million Oriented towards creating social value

Covering more than 20000 With approximately 200 Cumulative annual value of

hospitals nationwide employees and volunteers pharmaceuticals donated for public

participating in volunteer services welfare was approximately RMB 7.18 millionOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 70

Deepening Inclusive Healthcare Building a Better Society Together

Deepening Inclusive care medication accessibility to ensure equitable access to high-quality drugs

Healthcare across medical institutions at all levels. During the Reporting

As of the end of the reporting period 32

Salubris always adheres to the mission out of our 38 marketed drugs have been

of "improving patients' lives through included in the NRDL.exceptional medicines" improving

access to medicines and affordability 32

through fair pricing optimizing Promoting Access to marketed drugs have been

grassroots drug supply chain systems Medicines included in the NRDL.etc. aiming to eliminate regional and

socioeconomic disparities and bring Salubris continues to optimize

high-quality medical resources to its pharmaceutical supply chain

patients worldwide. system dedicated to enhancing the

continuous accessibility of medicines

in resource-constrained regions.Fair Pricing The Company has established a As of the end of the reporting

multi-channel distribution network period our extensive commercial

Salubris strictly complies with the integrating "in-hospital out-of- reach covered over

Price Law of the People's Republic of hospital and e-commerce" channels.China and drug price management By expanding its first- and second-

regulations actively building tier distributor networks it effectively

differentiated product pricing strategies covers grassroots and county-level

for the domestic market ensuring markets while vigorously developing 30+

equitable accessibility of medical "dual-channel" pharmacies and

resources in regions with different provincial-level administrative DTP (Direct-to-Patient) pharmacies.economic development levels. regionsSimultaneously we are actively

In the domestic market the expanding into new retail models

Company actively aligns with collaborating with major e-commerce

national medical insurance reform platforms such as JD.com Alibaba 20000+

policies. By participating in insurance and Meituan as well as the top 100 hospitals

negotiations it facilitates the inclusion national pharmacy chains to improve

of innovative drugs in national and local medicine delivery efficiency in remote

reimbursement lists thereby reducing areas and enhance convenience for

patient out-of-pocket costs and patients purchasing medications.alleviating medication burdens. As of the end of the reporting period 100000+

Meanwhile the Company supports the Company has covered over 20000 retail pharmacies

adjustments to the National Essential hospitals and more than 100000 retail

Medicines List and centralized pharmacies across over 30 provincial

procurement policies optimizing primary regions in China.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 71

Deepening Inclusive Healthcare Building a Better Society Together

Promoting Access to Case Carrying Out Medical Personnel Training Empowering Clinical Level Improvement

Healthcare Technology

Salubris is committed to

breaking down information

barriers and strengthening the The Company in collaboration with the China Medical Foundation launched the "Non-Dialysis-Dependent

capacity building of medical (NDD) Anemia Screening Registration and Education Special Project." This initiative provides ongoing training

staff in grassroots and general for nephrologists and nurses nationwide. The curriculum covers screening standards for anemia in non-dialysis

hospitals. Through collaboration chronic kidney disease (CKD) individualized management of hemoglobin (Hb) targets and standardized clinical

with healthcare organizations at application of EnNaLuo complemented by practical instruction on a digital screening system.all levels industry associations

and public welfare foundations Additionally the Company partnered with Beijing United Heart Foundation under the guidance of the

the Company aims to achieve Cardiovascular Disease Branch of the Chinese Medical Association carrying out chronic disease standardized

inclusive sharing of diagnostic and diagnosis and treatment public welfare training providing comprehensive empowerment for cardiovascular

treatment technologies. nephrology geriatric and general practitioners promoting overall significant advancement of clinical diagnostic

and treatment levels.Medical Personnel Training SiteOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 72

Deepening Inclusive Healthcare Building a Better Society Together

Case Collaborating with the Chinese Medical Doctor Association and the China Health Promotion and Education Association to strengthen capacity building for grassroots medical staff

In 2025 Salubris partnered with the Chinese Medical Doctor Association

and the China Health Promotion and Education Association to launch

the "Excellent General Practitioner Training Program" and the "Benchmark

Community Visit Project." Leveraging diverse formats such as on-site

visits to benchmark communities lectures on the latest guidelines

scenario-based workshops case simulations and community health

clinics the initiative aims to enhance the comprehensive chronic

disease management capabilities of grassroots medical personnel

particularly key physicians. This effort injects momentum into

accelerating the turning point in cardiovascular disease prevention and

control across China.Enhancing Chronic Disease Screening and Equitable Access to Health Services

Salubris consistently regards the improvement of public health and well-being as a core responsibility. The company is

dedicated to advancing early screening and diagnosis of chronic diseases and ensuring inclusive equitable access to health

services contributing to the development of a health protection network that reaches grassroots communities.Case Launched World Hypertension Day Community Health Clinic Initiative to Support Grassroots Chronic Disease Prevention and Control

On May 17 2025 in observance of the 21st World Hypertension Day

Salubris partnered with Shenzhen's healthcare system and multiple

hospitals to launch a community outreach initiative under the theme

"Stable blood pressure morning and night is true blood pressure control."

Covering seven districts across Shenzhen the initiative brought together

eight hospitals at the municipal level or above and nearly 100 medical

experts to conduct 11 free health screening and consultation sessions.More than 2000 residents received professional medical consultations

and services. The campaign educated the public on hypertension

prevention promoted early screening diagnosis and treatment raised

awareness of morning and evening blood pressure monitoring extend

high-quality healthcare resources to grassroots communities strengthen

primary-level chronic disease prevention and management and support Free medical consultation site

the Healthy Shenzhen and Healthy China initiatives.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 73

Deepening Inclusive Healthcare Building a Better Society Together

Building a Better Society Together Case Carrying Out "EnNaLuo" and "Osteoporosis" Special Drug Assistance Projects

Salubris regards public welfare charity as an important component of the

Company's sustainable development strategy. Closely aligning with the "Healthy

China" and "Rural Revitalization" national strategies the Company focuses on Salubris operates "EnNaLuo" and "Osteoporosis" special drug assistance

medical health and rural revitalization actively fulfilling social responsibilities. projects on an ongoing basis giving free donated drugs to qualified

In 2025 Salubris's total charitable donation amount reached RMB 27.1 million renal anemia and osteoporosis patients effectively alleviating patients'

mobilizing nearly 200 employees and volunteers to participate in volunteer services economic burdens guaranteeing patients' continuous standardized

accumulating service hours of 1965 hours. treatment synchronously carrying out grassroots medical personnel

capacity-building support helping improve grassroots medical service

quality and efficiency.Medical Donations

Drawing on its robust R&D and manufacturing capabilities Salubris has established

a systematic charitable drug donation program. The Company regularly donates

essential medicines to primary healthcare facilities in rural areas and patients in

underserved regions. The Company has implemented long-term targeted medical

aid programs in Guangdong Guangxi Xinjiang Sichuan Tibet Hunan and other

regions across China. In 2025 cumulative donated public welfare drug value

reached approximately RMB 7.18 million.At the same time the Company organized physician volunteers to travel to rural

areas for free chronic disease clinics simultaneously distributing complimentary

medications. This initiative specifically supplements therapeutic drugs at township Emergency Drug Aid for Myanmar

health centers effectively alleviating the medication burden on grassroots Case Earthquake Victims

communities and addressing supply gaps in local medical institutions. By

implementing multiple measures the Company has expanded the coverage of

high-quality medicines extending to remote areas thereby significantly improving

medication accessibility for grassroots populations. Responding to national calls we

actively participated in disaster

During the Reporting Period relief material assistance actions.

27.1 In March 2025 Salubris provided RMB million RMB 7.18 million international humanitarian

Salubris's total charitable donation cumulative donated public welfare assistance by donating anti-

amount reached drug value reached approximately infective medicines worth more

than RMB 2 million to communities

200 affected by the earthquake in 1965 Myanmar supporting post-disaster with approximately 200 employees hours disease prevention and control Disaster Area Drug Donation

and volunteers participating in accumulating service hours efforts.volunteer servicesOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 74

Deepening Inclusive Healthcare Building a Better Society Together

Rural Revitalization

Addressing essential needs in rural communities we have implemented a range

of livelihood infrastructure projects including rural road improvements upgrades

to village-level health stations and the development of rural cultural plazas.These initiatives aim to improve transportation healthcare cultural and sports

infrastructure and contribute to sustainable rural development.Case Empowering Rural Youth to Co-create a Sustainable Future

Salubris sponsored the "Second SDGs Rural Sustainable DevelopmentYouth Co-creation Camp” focusing on rural revitalization and youth

development. By establishing an integrated industry-academia-

research platform the project inspired university students to contribute

their ideas and empowered rural youth to engage in sustainable

development practices effectively promoting educational equity and

capacity building in rural areas. For this initiative Salubris received two

awards from the "Responsibility 100 | CSR China Education List": "Best

Responsible Enterprise Brand" and "Outstanding Youth Impact Project."

Second SDGs Rural Sustainable Development Youth Co-creation CampOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 75

Appendix I Appendix II Appendix III Our Listening

A ppendix I: Key Performance Table

Environmental

Indicator Unit 2025

Greenhouse Gas Emissions

Total greenhouse gas emissions tCO2e 64586

Scope 1 Greenhouse Gas Emissions tCO2e 9897

Scope 2 Greenhouse Gas Emissions tCO2e 54689

Greenhouse Gas Emission Intensity tCO2e / RMB million of revenue 14.84

Emissions

Total wastewater discharge tonnes 588096

Total wastewater pollutant discharge tonnes 98.46

Chemical Oxygen Demand (COD) tonnes 94.82

Ammonia nitrogen tonnes 3.55

Total phosphorus tonnes 0.09

Total waste gas discharge m3 1176758474

Particulate matter tonnes 1.59

Nitrogen oxides tonnes 6.97

Sulfur oxides tonnes 0.78

Volatile organic compounds (VOCs) tonnes 11.93

Total non-hazardous waste tonnes 1264

Non-hazardous waste intensity tonnes/RMB million of revenue 0.29

Total hazardous waste tonnes 4915

Hazardous waste intensity tonnes/RMB million of revenue 1.13

Energy Consumption

Natural gas m3 4466810

Gasoline tonnes 21

Diesel tonnes 3

Purchased electricity MWh 73503

Purchased Heat GJ 138615Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 76

Appendix I Appendix II Appendix III Our Listening

Indicator Unit 2025

Comprehensive energy consumption tonnes of standard coal equivalent 19739

Comprehensive energy consumption intensity tonnes of standard coal equivalent/RMB million of revenue 4.53

Total water consumption tonnes 848190

Total water intensity tonnes/RMB million of revenue 194.87

Water withdrawal volume tonnes 779914

Water consumption volume tonnes 191819

Water resource recycling volume tonnes 68276

Industrial Water Reuse Rate % 8.75

Packaging Material Usage tonnes 3169

Packaging Material Usage Intensity tonnes/RMB million of revenue 0.73

Social

Indicator Unit 2025

Product Quality and Safety

Commercialized Product Release Pass Rate % 100

Market Supervision Sampling Inspections Pass Rate % 100

Product Quality Training Coverage Rate % 100

Number of Product Recalls / 0

Percentage of Products Subjected to Recall for Health and Safety Reasons % 0

Technological Innovation

R&D Investment Amount RMB hundred million 12.66

R&D Investment as a Percentage of Annual Revenue % 29.10

Number of R&D Personnel persons 827

Percentage of R&D Personnel % 20.23

Patent Application Filed Count items 241

Among Which: Invention Patent Application Filed Count items 226

Patent Grant Count items 63

Among Which: Invention Patent Grant Count items 56

Cumulative Valid Patent Grant Count items 392Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 77

Appendix I Appendix II Appendix III Our Listening

Indicator Unit 2025

Customer Service

Total Customer Complaints times 67

Major Complaint Event Count times 0

Customer Complaint Processing Rate % 100

Supplier Management

Number of Suppliers / 2594

Mainland China / 2584

Number of Suppliers by Region

Hong Kong Macao Taiwan and Overseas / 10

Number of Key Suppliers / 308

Suppliers Certified by ISO 14001 System / 186

Suppliers Certified by ISO 45001 System / 169

Supplier Certification

Suppliers Certified by ISO 9001 System / 293

Suppliers Certified by Other Certifications / 130

Suppliers Using Eco-friendly Materials and Circular Packaging / 21

Overdue Payments to Small and Medium-sized Enterprises RMB 10000 0

Employee Employment

Total Number of Employees persons 4087

Male persons 2114

By Gender

Female persons 1973

30 years old and below persons 1171

By Age Group 30-50 years old (inclusive) persons 2751

Above 50 years old persons 165

Doctoral Degree or Above persons 68

Master's Degree persons 427

By Education Level

Bachelor's Degree persons 1861

Associate Degree or Below persons 1731

General Employees persons 3632

By Job Level Middle Management persons 439

Senior Management persons 16

Mainland China persons 4055

By Region

Hong Kong Macao Taiwan and Overseas persons 32Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 78

Appendix I Appendix II Appendix III Our Listening

Indicator Unit 2025

Han Ethnicity persons 3834

By Ethnicity/Race Ethnic Minorities persons 215

Overseas persons 38

Production persons 1154

Technical persons 827

By Profession

Sales persons 1698

General persons 408

Full-time Employees persons 3940

By Employment Type

Non Full-time Employees persons 147

Female in Junior Management persons 117

Female in Middle Management persons 115

Employee Diversity Female in Senior Management persons 5

Female in STEM-related Positions persons 698

Female Managers in Revenue-generating

persons 138

Positions

Total New Hires persons 1053

Male persons 501

Female persons 552

New Recruitment

30 years old and below persons 526

30-50 years old (inclusive) persons 521

Above 50 years old persons 6

Employee Turnover

Turnover Rate % 16

Male Turnover Rate % 17

Turnover Rate By Gender

Female Turnover Rate % 15

30 years old and below % 23

Turnover Rate By Age Group 30-50 years old (inclusive) % 13

Above 50 years old % 13

Mainland China % 16

Turnover Rate By Region

Hong Kong Macao Taiwan and Overseas % 0

General Employees % 16

Turnover Rate By Job Level Middle Management % 13

Senior Management % 0Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 79

Appendix I Appendix II Appendix III Our Listening

Indicator Unit 2025

Employee Development

Percentage of Employees Trained % 100

Male persons 2114

By Gender Training Coverage

Female persons 1973

Male % 100

Gender Training Percentage

Female % 100

General Employees persons 3632

By Job Level Training Coverage Middle Management persons 439

Senior Management persons 16

General Employees % 100

By Job Level Training Percentage Middle Management % 100

Senior Management % 100

Total Annual Training Hours hours 240296

Average Training Hours per Employee hours 59

Male hours 62

By Gender Average Training Hours

Female hours 56

General Employees hours 59

By Job Level Average Training Hours Middle Management hours 57

Senior Management hours 18

Number of Employees Under Performance Appraisal or Career Development

Assessment persons 3651

Percentage of Employees Under Performance Appraisal or Career Development

Assessment % 90

Occupational Health and Safety

Number of Work-Related Deaths persons 0

Lost Workdays Due to Work Injuries days 97

Total Recordable Incident Rate (TRIR) incidents per 200000 working hours 0.0970

Lost Time Injury Rate (LTIR) incidents per 200000 working hours 0.0970Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 80

Appendix I Appendix II Appendix III Our Listening

Indicator Unit 2025

Near-miss Report Rate incidents per 200000 working hours 98

Hazard Rectification Rate % 99.66

Contractor Lost Time Injury Accident Events incidents 0

Work Injury Insurance Investment Amount RMB 10000 301

Work Injury Insurance Coverage persons 3936

Total Person-Times of Occupational Health and Safety Training person-times 35392

Total Duration of Occupational Health and Safety Training hours 44770

Total Sessions of Occupational Health and Safety Training times 861

Total Sessions of Occupational Health and Safety Training Conducted for

Contractors times 158

Covered Number of Contractors for Occupational Health and Safety Training persons 1754

Coverage Rate of Occupational Health and Safety Training for Contractors % 100

Total Training Hours for Contractors hours 978

Certification Rate for Special Operations Personnel % 100

Occupational Health Examination Rate of Occupational Disease Risk Post

% 100

Employee

Number of Occupational Disease Risk Post Employees persons 964

Number of Employees Participating in Occupational Health Examination persons 964

Number of Employees with Occupational Disease Incidence persons 0Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 81

Appendix I Appendix II Appendix III Our Listening

Governance

Indicator Unit 2025

Corporate Governance

Number of Board Meetings Held times 9

Director Attendance Rate % 100

Information Security and Privacy Protection

Total Number of Data Security Incidents incidents 0

Total Number of Customer Privacy Breach Incidents incidents 0

Financial Impact of Data Security Incidents RMB 10000 0

Financial Impact of Customer Privacy Breach Incidents RMB 10000 0

Percentage of Regular Employees Participating in Information Security Training % 100

Number of Information Security Audits times 2

Community Welfare

Total amount of charitable donations RMB 10000 2710

Total hours of participation in charitable activities hours 1965Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 82

Appendix I Appendix II Appendix III Our Listening

Appendix II: Index of the ESG Code of the Hong Kong Stock Exchange

KPIs Corresponding Chapters

Category: Environment

A1 Emissions

General Disclosure 4.4 Promoting Green Operations

A1.1 The types of emissions and respective emissions data 4.4 Promoting Green OperationsKey Performance Indicator Table

A1.3 Total hazardous waste produced (in tonnes) and where appropriate intensity (e.g. per unit of 4.4 Promoting Green Operationsproduction volume per facility). Key Performance Indicator Table

A1.4 Total non-hazardous waste produced (in tonnes) and where appropriate intensity (e.g. per unit of 4.4 Promoting Green Operationsproduction volume per facility). Key Performance Indicator Table

A1.5 Description of emission target(s) set and steps taken to achieve them. 4.4 Promoting Green Operations

A1.6 Description of how hazardous and non-hazardous wastes are handled and a description of waste reduction target(s) set and steps taken to achieve them. 4.4 Promoting Green Operations

A2 Use of Resources

General Disclosure 4.3 Practicing Resource Conservation

A2.1 Direct and/or indirect energy consumption by type (e.g. electricity gas or oil) in total (kWh in’ 000s)

4.3 Practicing Resource Conservation

and intensity (e.g. per unit of production volume per facility). Key Performance Indicator Table

4.3 Practicing Resource Conservation

A2.2 Water consumption in total and intensity (e.g. per unit of production volume per facility).Key Performance Indicator Table

A2.3 Description of energy use efficiency target(s) set and steps taken to achieve them. 4.3 Practicing Resource Conservation

A2.4 Description of whether there is any issue in sourcing water that is fit for purpose water efficiency target(s) set and steps taken to achieve them. 4.3 Practicing Resource Conservation

A2.5 Total packaging material used for finished products (in tonnes) and if appropriate with reference

4.3 Practicing Resource Conservation

to per unit produced. Key Performance Indicator TableOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 83

Appendix I Appendix II Appendix III Our Listening

KPIs Corresponding Chapters

A3 The Environment and Natural Resources

General Disclosure 4.2 Strengthening Environmental Management

A3.1 Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them. 4.2 Strengthening Environmental Management

Category: Social

Employment and Labor Practices

B1: Employment

General Disclosure 3.1 Implementing Compliant Employment

B1.1 Total workforce by gender employment type (for example full- or part-time) age group and 3.1 Implementing Compliant Employmentgeographical region. Key Performance Table

B1.2 Employee turnover rate by gender age group and geographical region. 3.1 Implementing Compliant EmploymentKey Performance Table

B2: Health and Safety

General Disclosure 3.4 Ensuring Health and Safety

B2.1 Number and rate of work-related fatalities occurred in each of the past three years including the reporting year. 3.4 Ensuring Health and Safety

B2.2 Lost days due to work injury. 3.4 Ensuring Health and Safety

B2.3 Description of occupational health and safety measures adopted and how they are implemented and monitored. 3.4 Ensuring Health and Safety

B3: Development and Training

3.2 Empowering Employee Growth

General Disclosure 3.3 Unlocking Employee Potential

Key Performance Table

B3.1 The percentage of employees trained by gender and employee category (e.g. senior 3.2 Empowering Employee Growth management middle management). Key Performance Table

B3.2 The average training hours completed per employee by gender and employee category. 3.2 Empowering Employee Growth Key Performance TableOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 84

Appendix I Appendix II Appendix III Our Listening

KPIs Corresponding Chapters

B4: Aspect Labour Standards

General Disclosure 3.1 Implementing Compliant Employment

B4.1 Description of measures to review employment practices to avoid child and forced labour. 3.1 Implementing Compliant Employment

B4.2 Description of steps taken to eliminate such practices when discovered. 3.1 Implementing Compliant Employment

Operating Practices

B5: Aspect Supply Chain Management

General Disclosure 2.4 Industrial Synergy and Common Prosperity

B5.1 Number of suppliers by geographical region. 2.4 Industrial Synergy and Common Prosperity

B5.2 Description of practices relating to engaging suppliers number of suppliers where the practices are being implemented and how they are implemented and monitored. 2.4 Industrial Synergy and Common Prosperity

B5.3 Description of practices used to identify environmental and social risks along the supply chain and how they are implemented and monitored. 2.4 Industrial Synergy and Common Prosperity

B5.4 Description of practices used to promote environmentally preferable products and services when selecting suppliers and how they are implemented and monitored. 2.4 Industrial Synergy and Common Prosperity

B6: Product Responsibility

General Disclosure 2.1 Keeping Quality Commitments

B6.1 Percentage of the total products sold or shipped subject to recalls for safety and health reasons. 2.1 Keeping Quality Commitments

B6.2 Number of products and service related complaints received and how they are dealt with. 2.3 Putting Patients First

B6.3 Description of practices relating to observing and protecting intellectual property rights. 2.2 Focusing on Technological Innovation

B6.4 Description of quality assurance process and recall procedures. 2.1 Keeping Quality Commitments

B6.5 Description of consumer data protection and privacy policies and how they are implemented and monitored. 1.4 Information Security and Privacy Protection

B7: Anti-corruption

General Disclosure 1.3 Practicing Business Ethics

B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases. 1.3 Practicing Business EthicsOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 85

Appendix I Appendix II Appendix III Our Listening

KPIs Corresponding Chapters

B7.2 Description of preventive measures and whistle-blowing procedures and how they are implemented and monitored. 1.3 Practicing Business Ethics

B7.3 Description of anti-corruption training provided to directors and staff. 1.3 Practicing Business Ethics

Community

B8 Community investment

General Disclosure 5.2 Building a Better Society Together

Focus areas of contribution (e.g. education environmental issues labour needs health culture

B8.1 5.2 Building a Better Society Together

and sport).B8.2 Resources contributed (e.g. money or time) to the focus area 5.2 Building a Better Society Together

Climate-related disclosures

Governance Governance 4.1 Responding to Climate Change

Climate-related risks and opportunities 4.1 Responding to Climate Change

Business model and value chain 4.1 Responding to Climate Change

Strategy and decision-making 4.1 Responding to Climate Change

Strategy

Financial position financial performance and cash flows 4.1 Responding to Climate Change

Climate resilience 4.1 Responding to Climate Change

Financial impacts of climate-related risks and opportunities 4.1 Responding to Climate Change

Risk management Risk management 4.1 Responding to Climate Change

Greenhouse gas emissions 4.1 Responding to Climate Change

Climate-related transition risks 4.1 Responding to Climate Change

Climate-related physical risks 4.1 Responding to Climate Change

Metrics and Targets Climate-related opportunities 4.1 Responding to Climate Change

Not applicable. During the reporting period

the Company had no specific material capital

Capital deployment expenditure related to climate-related risks and

opportunities and did not engage in any climate-

related financing or investing activities.Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 86

Appendix I Appendix II Appendix III Our Listening

KPIs Corresponding Chapters

Not applicable. The Company does not currently

Internal carbon prices

use an internal carbon price.Not applicable. The Company has not yet

Remuneration incorporated climate-related factors into its

remuneration policy.Not applicable. Industry-based metrics are not

Metrics and Targets Industry-based metrics applicable to the Company

Climate-related targets 4.1 Responding to Climate Change

Cross-industry metrics: 4.1 Responding to Climate

Change.Applicability of cross-industry metrics and industry-based metrics

Industry-based metrics are not applicable to the

CompanyOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 87

Appendix I Appendix II Appendix III Our Listening

A ppendix III: Index of the Self-Regulatory Guidelines No. 17 for Companies Listed on Shenzhen

Stock Exchange—Sustainability Report (For Trial Implementation)

Dimension No. Issues Corresponding Clauses Corresponding Chapters

1 Climate Change Article 21 to Article 28 4.1 Responding to Climate Change

2 Pollutant Emissions Article 30 4.4 Promoting Green Operations

3 Waste Management Article 31 4.4 Promoting Green Operations

4 Ecosystem and Biodiversity Protection Article 32 4.4 Promoting Green Operations

Environmental

5 Environmental Compliance Management Article 33 4.2 Strengthening Environmental Management

6 Energy Utilization Article 35 4.3 Practicing Resource Conservation

7 Water Resource Utilization Article 36 4.3 Practicing Resource Conservation

8 Circular Economy Article 37 4.3 Practicing Resource Conservation

9 Rural Revitalization Article 39 5.2 Building a Better Society Together

10 Social Contribution Article 40 5.2 Building a Better Society Together

11 Innovation-Driven Development Article 42 2.2 Focusing on Technological Innovation

12 Technology Ethics Article 43 2.2 Focusing on Technological Innovation

Social 13 Supply Chain Security Article 45 2.4 Industrial Synergy and Common Prosperity

14 Equal Treatment of SMEs Article 46 2.4 Industrial Synergy and Common Prosperity

2.1 Keeping Quality Commitments

15 Product/Service Safety and Quality Article 47

2.3 Putting Patients First

16 Data Security and Customer Privacy protection Article 48 1.4 Information Security and Privacy Protection

3.1 Implementing Compliant Employment

3.2 Empowering Employee Growth

Social 17 Employees Article 50

3.3 Unlocking Employee Potential

3.4 Ensuring Health and Safety

18 Due Diligence Article 52 Not applicable.

Sustainability-

19 Stakeholder Engagement Article 53 Stakeholder Engagement

Related

20 Anti-Bribery and Anti-Corruption Article 55 1.3 Practicing Business Ethics

Governance

21 Anti-Unfair Competition Article 56 1.3 Practicing Business EthicsOverview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental Social and Governance (ESG) Report 88

Appendix I Appendix II Appendix III Our Listening

O ur Listening

Dear Reader

Greetings! Thank you for reading the 2025 Environmental Social and Governance (ESG) Report of Shenzhen Salubris Pharmaceuticals Co. Ltd. We highly value and welcome

your feedback on the Company’s ESG management practices and disclosure. Your comments and suggestions will serve as important references for us to continuously

improve our ESG management and practices. We look forward to your response!

1. Which stakeholder group does your organization belong to 5. How do you assess the comprehensiveness of the Company’s environmental

responsibilities reflected in this Report

Government & Regulators Shareholders & Investors Customers

Excellent Good Fair Poor

Consumers Employees Suppliers Partners Community the Public

6. How do you assess the comprehensiveness of the Company’s social

Others (please specify): responsibilities reflected in this Report

Excellent Good Fair Poor

2. How would you rate this Report

7. How would you rate the readability of the information provided in this Report

Excellent Good Fair Poor

Excellent Good Fair Poor

3. How would you rate the clarity accuracy and completeness of the information

and data disclosed in this Report

8. What information would you like to know that was not disclosed in this Report

Excellent Good Fair Poor

9. Do you have any comments and suggestions on the Company’s ESG

4. How do you assess the comprehensiveness of the Company’s economic performance and report preparation

responsibilities reflected in this Report

Excellent Good Fair Poor